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I. ABSTRACT 
Introduction: The prevalence of hepatocellular carcinoma (HCC) in Africa is higher compared 
to the rest of the world due to the high incidence of chronic infection with hepatitis C virus 
(HCV). In Egypt, HCV infection is the leading cause for the high HCC incidence, which is 
usually diagnosed at late stages. Due to the absence of reliable and accurate biomarkers for early 
detection of liver cancer, circulating microRNAs have recently emerged as great candidates for 
early diagnosis of HCC. These small non-coding RNA molecules are responsible for regulating 
gene expression and RNA stability. Therefore, the aim of this study is to investigate the potential 
of liver-specific circulating microRNAs as an accurate non-invasive diagnostic tool for the early 
detection of HCV-induced HCC.     
Methods: Eight main miRNAs (miR-16, miR-34a, miR-122a, miR-125a, miR-139, miR-145, 
miR-199a, and miR-221) were selected due to their expression patterns in HCC as well as their 
contribution to the development of hepato-carcinogenesis. A total of 165 patients were enrolled 
in this study, from which serum samples were collected and categorized into four main patient 
groups: 42 chronic hepatitis C (CHC) without cirrhosis, 45 CHC with cirrhosis (LC), 38 HCC 
with HCV patients, and 40 healthy controls. The expression profile of the eight miRNAs was 
analyzed using TaqMan real-time reverse transcription-polymerase chain reaction. Additionally, 
the conventional markers for HCC α-fetoprotein (AFP) and des-γ-carboxyprothrombin (DCP) 
were measured using commercial kits.  
Results: Serum levels of miRNA-122a, miRNA-125a, miRNA-139, miRNA-145 and miRNA-
199a were significantly lower (p<0.01) in HCC than in both CHC and LC groups. On the other 
hand, no significant difference was shown in the expression of miR-16, miR-34a, and miR-221 
between the CHC, LC, and HCC groups. MiR-16, miR-34a, and miR-221 were significantly 
elevated in the HCC group compared to the control group. MiR-122a showed the highest 
specificity and sensitivity, followed by miR-125a, which had the second highest specificity, 
indicating its significance in diagnosis.  
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Conclusions: The results indicated that measurement of serum levels of miR-122a, miR-125a, 
miR-139, miR-145, and miR-199a can help to differentiate HCC from CHC and LC. 
Measurement of serum levels of miR-16, miR-34a, and miR-221 were shown to have a 
prognostic value. Highly significant correlation was established between different miRNAs 
within the same patient group or between two different groups, indicating a great diagnostic 
value for the early detection of HCC. MiR-122a had the highest specificity and sensitivity, 
indicating that serum miR-122a might serve as a novel and potential non-invasive biomarker for 
HCV-induced HCC.  
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II. INTRODUCTION 
The significance of reliable biomarkers is usually illustrated by their usefulness during the 
course of a certain disease. In other words, biomarkers are evaluated based on their ability to be 
easily detected at the early onset of the disease, their efficacy in risk classification, and their 
sensitivity and specificity for disease progression and prognosis (Schöler et al., 2010). A 
biomarker is defined as a molecule that can be measured and assessed, one that indicates the 
proper functioning of biological processes, normal pathologies, or the pharmacological response 
to therapeutic drugs. Therefore, a reliable and accurate biomarker must lack limitations such as 
low sensitivity and specificity, low predictive power, and robustness, in addition to exerting 
noninvasiveness characteristics (Schöler et al., 2010).  
In 1993, Lee et al. was the first to discover the small noncoding RNA lin-4 in Caenorhabditis 
elegans, which is now known to be the founding member of 17341 annotated mature 
microRNAs (miRNAs) in 142 species, out of which 1048 are human mature miRNAs (Lee, 
Feinbaum, & Ambros, 1993; Wang, Chen, & Sen, 2016). Approximately 20% of all annotated 
miRNAs are highly conservative between organisms like C. elegans and Homo sapiens. 
MiRNAs are assumed to target more than 60% of the human genes, hence their high abundance 
in mammalian cells. Several research groups have illustrated the deregulation of miRNAs in 
various pathological processes, which was evident in the development of many diseases as well 
as malignancies (Schöler et al., 2010).  
 Measuring the levels of circulating miRNAs to be used as biomarkers for malignancies 
has recently been researched and investigated. This diagnostic approach shows a lot of promise 
due to the high stability of miRNAs in human formalin-fixed tissue, serum, and plasma, in 
addition to their tissue specific expression pattern shown in human malignancies (Qu et al., 2011 
& Barger et al., 2016). The hepatocellular carcinoma (HCC) conventional biomarkers are usually 
able to detect large tumors, which was evident with the relatively high sensitivity when 3 HCC 
biomarkers were used to detect HCC in patients with large tumors. However, for an aggressive 
cancer such as HCC, early detection is key to a better therapeutic response and prognosis (Qu et 
al., 2011).    
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 A microarray chip identifying the global normal levels of each member of the miRNome 
has been developed in order to enable the comprehensive and efficient profiling of all miRNA 
genes (Liu et al., 2004). With more research being conducted on the subject, more technologies 
became available, such as quantitative reverse transcription PCR, macroarrays, and bead-based 
flow cytometric miRNA expression. Together, these technologies have illustrated the differential 
expression of human miRNAs in tissues and helped in identifying crucial miRNA genes that play 
key roles in the development of human diseases (Aqeilan et al., 2010). Researchers have been 
working in the hope of identifying unique miRNA signatures in human tumors that will help in 
better understanding cancer pathways and carcinogenesis in general, thus facilitating the proper 
design of effective diagnostic, therapeutic, and prognostic tools. Number of miRNAs were 
shown to play a crucial role in cancer development. MiRNAs that are found to be upregulated in 
tumors function as oncogenes, while other miRNAs have been described as tumor suppressors 
due to their loss or down-regulation. Moreover, some miRNAs have been identified for their 
function in metastasis and angiogenesis (Aqeilan et al., 2010).  
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III. LITERATURE REVIEW 
The liver is known to be the largest internal organ, it is divided into two main lobes, right and 
left, and it is located under the right ribs and beneath the right lung, with a weight of 
approximately three pounds. It is a major vascular organ that receives approximately up to 25% 
of the entire cardiac output, which is substantially more than the rest of the body’s organs 
combined. It has two blood supplies divided between the hepatic artery, which is responsible for 
25% to 30% of the blood supply to the liver, and the portal vein which supplies the other 70% to 
75% (Abdel-Misih & Bloomston, 2010). The liver has several significant functions that support 
other organs, impacting all physiologic systems. One of the main liver functions is metabolism 
and protein synthesis, in addition to metabolizing amino acids, lipids, carbohydrates, and 
vitamins. The liver also performs the crucial function of detoxifying the systematic circulation 
through the removal of pathogens and exogenous antigens (Bogdanos et al., 2013). It has a 
significant immunological function, since its reticuloendothelial ability is responsible for 
phagocytosis and clearance of endotoxins and microorganisms from the portal blood. Bile 
secretion is a crucial end point of liver function; hence bile production immediately stops when 
liver perfusion is halted. The unique location of the liver as well as its special vasculature allows 
it to perform the degradation of waste products and toxins (Hoekstra et al., 2013).  
A. Hepatitis C Virus 
Hepatitis C infection is a disease that infects the liver as a result of hepatitis C virus (HCV) 
infection, an RNA virus discovered in 1989 that belongs to the Flaviviridae family. HCV 
infection leads to acute hepatitis C, which develops into a chronic infection in 50-80% of HCV 
patients. HCV chronic infection activates a chronic inflammatory disease response, which leads 
to the development of liver fibrosis, cirrhosis, and hepatocellular carcinoma (Manns et al., 2017). 
The HCV virions are enveloped in a lipid bilayer with a diameter of 45-65 nm. The non-
icosahedral nucleocapsid is located inside the envelope, and is made up of the positive-strand 
RNA as well as several copies of the basic HCV core protein (Penin, Dubuisson, Rey, 
Moradpour, & Pawlotsky, 2004). Phylogenetic analyses of HCV strains collected from different 
geographical regions revealed that HCV has seven different genotypes, thus making it a very 
heterogeneous virus. Additionally, HCV genotypes include multiple subtypes that are 
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represented by lower-case letters. The severity of the disease as well as the response to antivirals 
depend on the genotype (Figure 1) (Simmonds, 2013). 
The global prevalence of HCV patients who are positive for anti-HCV antibodies was 
estimated to be 1.6%, which is equivalent to approximately 115 million patients (Gower, Estes, 
Blach, Razavi-Shearer, & Razavi, 2014). However, not all these individuals currently have HCV; 
some have cleared the virus after receiving treatment or spontaneously. Therefore, the global 
prevalence for patients with HCV RNA is approximately 71 million patients. This incidence is 
based on mega epidemiological studies that have been conducted in 100 countries. Global 
statistical data is limited since the HCV prevalence is only reported by 29% of the low-income 
countries and 60% of high-income countries (The Polaris Observatory HCV Collaborators, 
2017). The prevalence of HCV infection varies globally, in which the countries with the highest 
prevalence are those with highest rates of iatrogenic infections. Iatrogenic infection is the major 
risk factor for the high prevalence of HCV in countries like Gabon, Nigeria, Egypt, Mongolia, 
Georgia, and Uzbekistan, where the prevalence is >5% in the adult population (Figure 2) 
(Gower, Estes, Blach, Razavi-Shearer, & Razavi, 2014).  
The percentage of the global HCV infection in Western countries is small compared to that 
of countries like Russia, China, Egypt, India, and Pakistan where half of the total viraemic HCV 
infections is located (Manns et al., 2017). In Egypt, the high prevalence of HCV is attributed to 
the schistosoma intravenous injections in the 1960-1970s (Figure 3) (Arafa et al., 2005; Ministry 
of Health and Population, El-Zanaty and Associates, & ICF International, 2015). Intravenous 
injections of anti-schistosomal therapy were nationwide under the supervision of the Egyptian 
Ministry of Health (MOH) and the World Health Organization (WHO). An average of 250,000 
patients received more than 2 million injections annually. Approximately 36 million injections 
were given to >6 million patients over a period of 18 years, in which the majority of needles and 
syringes were not properly sterilized or disposed (Frank et al., 2000; Rao et al., 2002).  
In Egypt, HCV infection is the major cause of liver diseases, such HCC. Approximately 1-
5% of cirrhotic patients develop liver cancer, in which 3-6% may decompensate during a period 
of 20-30 years. One year after decompensation the risk of death is 15-20% (Westbrook & 
Dusheiko, 2014). A systematic review based on 13 studies that included 2,386 patients 
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demonstrated that the annual percentage of death/transplantation, decompensation, and HCC 
among compensated HCV cirrhotic patients is 4.58%, 6.37%, and 3.36%, respectively (Alazawi, 
Cunningham, Dearden, & Foster, 2010).   
 
Figure 1. Distribution of HCV Genotypes. Six of the seven genotypes are shown here according to their 
distribution, which is different between countries based on the categories of the World Bank income. In Europe, 
the Americas, Australia, Central and East Asia, and New Zealand, genotype 1 is shown to be the most 
prevalent. Genotype 4 is the most predominant genotype in Egypt and Central sub-Saharan Africa, while 
genotype 3 is predominant in India and Pakistan. In South Africa, genotype 5 is responsible for more than one-
third of HCV infections, while South East Asia is where genotype 6 is most commonly found. Adapted with 
permission from Manns et al., 2017.      
 
Figure 2. Global Prevalence of HCV. A geographical representation of the prevalence of viraemic hepatitis C 
virus (HCV) and the estimated total HCV infections per country. Adapted with permission from Manns et al., 
2017.      
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Figure 3. Prevalence of HCV in Egypt. The percentage among men and women in Egypt with hepatitis C 
antibody in 2015. Adapted with permission from Gomaa et al., 2017.      
B. Fibrosis and Cirrhosis  
Over the past few decades, liver fibrosis has evolved from being a laboratory discipline into a 
field of significant clinical relevance to hepatologists. This progress not only reflects the growing 
understanding of fibrosis molecular basis, but also of its natural history as well as the detection 
methods of chronic liver diseases (Friedman, 2003). Such advances have illustrated that cirrhosis 
can be changed, in which antifibrotic therapy can greatly change the management and prognosis 
of liver disease patients. Cirrhosis is known as the final stage of fibrosis of the hepatic 
parenchyma as a result of nodule formation as well as the change in hepatic functions (Friedman, 
2003).  
Fibrosis and cirrhosis are defined as the progression of a continuous wound healing response 
to chronic liver disease from different etiologies like viral, drug induced, cholestatic, 
autoimmune, and metabolic diseases. The clinical symptoms of cirrhosis usually range from no 
sign of symptoms to liver failure, which is usually determined by the nature and the extent of the 
liver disease etiology in addition to the magnitude of the hepatic fibrosis (Fattovich et al., 1997). 
Approximately 40% of cirrhotic patients remain asymptomatic for more than a decade; however, 
rapid deterioration is unavoidable as soon as complications such as encephalopathy, ascites, or 
variceal hemorrhage start to develop. Patients who suffer such complications have a 50% 5-year 
mortality, in which around 70% of them are as a result of the liver disease (Fattovich et al., 
1997). Cirrhosis affects hundreds of millions of individuals around the world where it is the most 
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common non-malignant cause of death among digestive and hepatobiliary diseases in the United 
States (El-Serag & Mason, 2000; Befeler & Di Bisceglie, 2002). 
The molecular makeup of the cirrhotic scar tissue is the same regardless of the underlying 
liver disease, it is composed of the constituents of the extracellular matrix, glycoproteins, 
collagen types I and III, and sulfated proteoglycans (Schuppan et al., 2001). Over time, these 
scar components accumulate due to the increase in their deposition in the liver. Although the 
most visible form of scarring is the cirrhotic bands surrounding nodules, it is in fact the 
accumulation of matrix molecules in the subendothelial space of Disse that results in the 
deterioration of liver function (Friedman, 2003).          
C. Hepatocellular Carcinoma (HCC) 
Hepatocellular carcinoma is categorized worldwide as the third most common cause of 
cancer-related death as well as the major cause of deaths among patients suffering from liver 
cirrhosis (Tinkle & Haas-Kogan, 2012). Additionally, it is the fifth most common cancer type in 
men and the seventh for women worldwide. The incidence of HCC in men is two to four times 
higher than it is in women. HCC is usually presented around the age of 40 years, where it reaches 
its peak at the age of 70 years (Ding & Wang, 2014). Every year, more than half a million 
individuals are diagnosed with HCC worldwide, with an estimate of 20,000 new cases only in 
the United States. Around 85% of the burden of the disease falls on the shoulders of developing 
countries. The highest reported rates of hepatitis B virus (HBV) are in Southeast Asia and sub-
Saharan Africa (El-Serag, 2011). HCC resulting from hepatitis C virus is becoming a fast-rising 
cause of cancer related deaths in the United States, in which the incidence has seen to be tripled 
during the past two decades while the 5-year survival rate still remained less than 12% (El-Serag, 
2011). Additional risk factors for HCC include non-alcoholic fatty liver disease, high alcohol 
intake, alpha1-anitrypsin deficiency, Wilson’s disease, hemochromatosis, and autoimmune 
hepatitis. Aside from the genetic factors, the majority of HCC cases result from chronic 
inflammation and persistent liver injury (Ding & Wang, 2014). Over the past decades, there has 
been evidence demonstrating that hepatitis B and C viral proteins can directly stimulate 
oncogenic effects or increase the risk of hepatocellular transformation with hyperproliferative 
response as a result of chronic inflammation. Thus, regardless of the etiology, a proliferative 
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tissue and inflammatory microenvironment is a common preneoplastic liver feature (Ding & 
Wang, 2014). Symptoms related to HCC are typically absent, patients usually show symptoms 
related to cirrhosis, which is a condition found in 80-90% of HCC patients. As a result, the 
majority of HCC patients are diagnosed with an advanced stage of the disease, which excludes 
potentially curative approaches. This partially led to the 5-year overall rate of survival of 12% 
and an average survival post diagnosis of 6 to 20 months (Tinkle & Haas-Kogan, 2012). The 
absence of accurate diagnostic tools for early HCC detection as well as curative therapy, resulted 
in very poor patient prognosis. HCC morbidity and mortality are almost the same due to the fact 
that the majority of HCC patients are diagnosed at late stages of the disease where the cancer is 
significantly advanced for good therapeutic options (Ding & Wang, 2014).   
Approximately more than 700,000 HCC cases are diagnosed annually all over the world, 
with more than 600,000 deaths yearly due to HCC (Dhanasekaran et al., 2012). When HCC is 
presented with symptoms it is usually associated with nonspecific illnesses, such as pain in the 
right upper abdominal area, malaise, early satiety, and weight loss. The presentation of 
encephalopathy, jaundice, ascites, or variceal bleeding in patients suffering from liver cirrhosis 
raises doubts of HCC. It is rare that patients may complain of hypotension, severe abdominal 
pain and distension, and a severe drop in hematocrit as a result of the tumor rupturing as well as 
intraperitoneal bleeding.  HCC is known to be linked to several paraneoplastic syndromes that 
lead to cutaneous manifestations, erythrocytosis, hypercalcemia, hypoglycemia, severe watery 
diarrhea, and hypercholesterolemia. The most common sites of metastasis resulting from HCC 
include the adrenal gland, bone, lung, and regional lymph node regions (Tinkle & Haas-Kogan, 
2012).  
D. MicroRNAs: 
The potential of miRNAs was recognized shortly after their discovery in 1993 in C. elegans, 
in which their significance in diagnosis and therapy was thoroughly investigated. MiRNAs 
regulate the process of protein translation through binding to the complementary sequences in 
the 3’ untranslated region (UTR) of the target mRNA. Currently, there are over 2,500 human 
miRNAs in the miRBase, a database containing all the published miRNAs and their annotation. 
(Hayes, Peruzzi, & Lawler, 2014). The miRNA names in miRBase are represented as has-mir-
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121, in which the first three letters refer to the organism from which the miRNA was identified. 
In the database and the literature, the mature miRNA is referred to as miR-121, while the 
miRNA gene is referred to as mir-121. Different precursor sequences as well as genomic loci 
expressing the same mature sequences are referred to as hsa-mir-121-1 and hsa-mir-121-2. On 
the other hand, letter suffixes indicate mature sequences that are closely related, such as hsa-
miR-121a and hsa-miR-121b. Finally, in the case of insufficient data it might be challenging to 
determine which sequence is the predominant one; therefore, 5p (from the 5’ arm) or 3p (from 
the 3’ arm) is denoted after the miRNA identification number (ex. miR-142-5p) (Hikmet, 
Reyyan, Melda, & Burcu, 2016).   
E. Synthesis of MiRNAs: 
 The synthesis of miRNA is mainly divided into two stages, one that takes place inside the 
nucleus, while the other takes place in the cytoplasm (Chu et al., 2014). The majority of miRNAs 
are transcribed by RNA polymerase II from intergenic regions, introns and exons. The first RNA 
transcript is an RNA precursor known as primary miRNA (pri-miRNA). Usually the pri-miRNA 
ranges in length from 200 to several thousand nucleotides, which forms a highly structured stem 
loop (Figure 1). After that, ‘Drosha’, the cellular RNase III enzyme, cleaves the stem loop 
structure with the assistance of, the cofactor DiGeorge syndrome critical region gene 8 (DGCR8) 
in vertebrates and ‘Pasha’ in invertebrates (Lee et al., 2003; Denli, Tops, Plasterk, Ketting, 
Hannon, 2004; & Gregory et al., 2004). The cleavage results in an RNA hairpin intermediate 
structure approximately 70 nucleotides in size, called the precursor-miRNA (pre-miRNA) that 
has two distinguished nucleotide 3’ overhang. The following step of the synthesis of miRNA is 
the exportation of the pre-miRNA hairpin from the nucleus by a heterodimer made of exportin 5 
and the GTP bound form of cofactor Ras-related nuclear protein (RAN) that identifies and binds 
the two 3’ overhand ends of the pre-miRNA (Yi, Qin, Macara, & Cullen, 2003; Lund, Guttinger, 
Calado, Dahlberg, & Kutay, 2004). After being transferred to the cytoplasm, another cellular 
RNase III enzyme known as Dicer, attaches to the structured RNA along with cofactor 
Transactivation response RNA binding protein (TRBP) to start a second cleavage. After the 
cleavage the resulting product is a double stranded RNA, with two nt 3’ overhang about 17-22 
bp long. Out of the dsRNA, one stays attached to the Dicer for the formation of the mature 
miRNA while the remaining strand usually degrades (Gupta et al., 2014).   
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 Finally, the mature single stranded miRNA is generated with the help of helicases like 
RCK/p54 or Gemin3. The RISC loading complex (RLC) is formed by the association of TAR 
RNA binding protein or TARBP2 (TRBP), Argonaute 2 (Ago2), and Dicer (Chu et al., 2014). 
One of the most important components in the RISC complex is the Argonaute-2 (Ago-2) protein, 
which is a catalytically active ribonucleoprotein (Liu et al., 2004; Meister et al., 2004). The 
mature miRNA attached to the active RISC complex binds at 3’ UTR of the target sites of a 
certain mRNA resulting either in immediate inhibition of translation or the degradation of the 
target mRNA by the Ago2 protein in the RISC complex (Figure 4). In the case of vertebrates, 
only partial complementary miRNA is needed to recognize the mRNA targets; however, it is 
crucial to have high complementarity of miRNA within the “seed sequence”, which is a region in 
the mature miRNA located in nucleotides 2-8 (Gupta et al., 2014).  
 
Figure 4. The synthesis and function of MicroRNAs. The transcription of microRNA (miRNA) genes is 
carried out by RNA polymerase II. The primary miRNA transcripts are processed into pre-miRNA by the 
microprocessor complex (Drosha/DGCR8). After that the pre-miRNA is exported from the nucleus to the 
cytoplasm by exportin-5 and Ran-GTP, then processed into a RNA duplex by ribonuclease Dicer with the 
help of TRBP. The final product is 22 bp dsRNA, in which one strand stays bound to dicer that later form 
the mature miRNA, while the other strand gets degraded. Finally, the remaining strand gets associated with 
RNA-induced silencing complex (RISC) and argonuate 2 (Ago2), which targets gene silencing by either 
cleavage or translation inhibition. Different proteins or protein complexes are shown in colored ovals. RNA 
is depicted by red and blue lines. Adapted from Hayes & Chayama, 2016, open access article, no 
permission.   
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i. Key enzymes in the processing stage of pri-miRNA to pre-miRNA: 
 As shown by several research studies, Drosha and DGCR8 are considered to be key 
enzymes in regulating the processing from pri-miRNA to pre-miRNA in different kinds of 
malignant cells. However, for some miRNAs the processing from pri-miRNA to pre-miRNA 
does not depend on the complex DGCR8 and Drosha. In the case of HCC, both Drosha and 
DGCR8 were shown to be over-expressed in the tumor cells (Chu et al., 2014). According to Liu 
et al. out of the genes involved in the synthesis of miRNAs, DROSHA was found to be the most 
differentially expressed in HCC induced by HBV infection (Liu et al., 2011). Similarly, unusual 
expression of Drosha can be seen in breast, ovarian, and cervical cancers, indicating the 
involvement of Drosha in different types of tumors. Few studies have shown HBV can inhibit the 
activity of Drosha, in which it inhibits its promoter activity through HBx and hence down-
regulating the expression of Drosha, also the transcription factors SP1 and AP2a might help in 
facilitating the down-regulation (Chu et al., 2014).  
ii. Key enzymes involved in the nuclear exportation of pre-miRNA: 
 The nuclear exportation of pre-miRNA primarily depends of XPO-5, whose defect in 
cancerous cells may lead to the down-regulation of the global mature miRNAs. It was found that 
in many cancers the pre-miRNAs are retained inside the nucleus; therefore, a gene mutation in 
the nuclear transporter of the pre-miRNAs might be a reason for human cancers (Chu et al., 
2014). As a matter of fact, XPO5-inactivating mutations are always identified in several human 
tumors, implying that XPO5 might be considered a haplo-insufficient tumor-suppressor gene. 
During the entry of the cell cycle, elevation in miRNA is crucial in order to control gene 
expression. It was illustrated by Lwasaki et al. (2013) that XPO5 is induced by a post-
translational mechanism that is PI3K-dependent, in which the suppression of XPO5 interferes 
with the miRNA elevation resulting in a defected cellular proliferation at the G1/S transition. 
Additionally, XPO5 is not only responsible for the exportation of pre-miRNA from the nucleus 
to the cytoplasm, but also for the exportation of other non-miRNA molecules (Wild et al., 2010).  
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iii. Key enzymes involved in regulating the processing from pre-miRNA to mature 
miRNA: 
 As mentioned before, Dicer is the enzyme responsible for dicing and creating mature 
miRNA. The majority of miRNAs are known to be Dicer dependent. However, some scientists 
have reported that in the case of miR-451, its dicing and maturation actually depends on Ago2 
rather than Dicer (Cheloufi et al., 2010; Cifuentes et al., 2010). In humans, the gene Dicerl codes 
for Dicer, which then functions as a haplo-insufficient tumor suppressor gene (McCarthy, 2010).  
F. Epidemiology:  
Even though HCC is known to be the most common primary hepatic tumor globally, there 
are major differences in its incidences among different parts of the world, with the majority of 
cases found in developing countries. According to the GLOBOCAN report, 746,300 newly 
diagnosed HCC cases were reported worldwide in 2008, while 659,900 of HCC related deaths 
were reported in the same year (Figure 5) (Dhanasekaran et al., 2012). Over one million new 
cases of HCC are diagnosed annually worldwide, making HCC as the fifth most common cancer 
globally (Raphael et al., 2012). HCC has a high incidence to mortality ratio of 1.07, which 
categorizes it as the third most common cause of cancer-related deaths around the world. The 
majority of these cases are found in developing countries where 84% of the total worldwide 
incidence and 83% of the total deaths have been recorded. The worldwide distribution of HCC 
cases is parallel to the global incidences of HBV and HCV infections, where the majority of 
HCC cases are located in the regions where these viral infections are endemic. Generally, HCC 
illustrates a male dominance, in which it is displayed in two to four times more in males than in 
females (Jemal et al., 2011).  
There are some unusual trends in the worldwide incidence of HCC, for example, the 
incidence in Asian regions like Korea and China is declining in population-based studies, which 
is attributed to the high number of vaccinations against hepatitis B as well as the aflatoxin 
preventive measures. Unlike the declining rates in Asian countries, several regions in the 
developing world have been showing an increase in the HCC incidence, particularly in Japan and 
the United States. This acceleration in the HCC incidence is related to large number of adults 
who showed signs of HCV infections as a result of blood transfusions and intravenous drug use 
between the period of the 1960s until the 1980s (El-Serag & Mason, 2000). In Egypt, liver 
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cancer is one of the most common tumors due to the high incidence of HCV infection. In men, 
both liver and bladder cancers represent approximately 44% of all malignancies, while in women 
liver and breast cancers represent 45% of all female malignancies (Figure 6) (Ibrahim, Khaled, 
Nabiel, Baraka, & Kamel, 2014). In addition, the rapidly increasing incidence of diabetes, 
nonalcoholic steatohepatitis (NASH), obesity are suspected to have contributed to the increasing 
numbers of HCC patients worldwide. However, regardless of the etiology, the main risk factor in 
the majority (80-90%) of HCC cases worldwide is the existence of the preneoplastic cirrhotic 
liver. According to the current statistics, the HCC incidence in the United States will continue to 
increase over the next two or three decades (Dhanasekaran et al., 2012).  
G. HCC Molecular Classification:  
 Great expectations were anticipated from the field of molecular medicine to unravel the 
mysteries of the molecular pathogenesis of cancer for the great benefit of the patients (Bruix et 
al., 2014). Biomedical research aimed at achieving several goals, such as easily identifying 
patients with high risk factors, detecting common oncogenic pathways, and developing the 
personalized and targeted medicine approach. For various types of cancers goals outlined above 
have been achieved, however for other types these goals have been marred by a slow rate of 
progress. The process of carcinogenesis is far more complicated than what is already known due 
to the abundance of genetic heterogeneity and the difficulty of accurately mapping the numerous 
genetic pathways (Yap et al., 2012). Other factors which contribute to this complicated process 
include the changing of genetic information in nature and the need to study cancer pathways in 
comparison to those of the non-tumor tissue in order to identify the changes in the tumor tissue.  
Cancer changes over time as the disease progresses, and therefore, various genetic 
features important for carcinogenesis differ and develop during metastasis. Since human tissue 
used for genetic analysis is usually obtained from surgical specimens, this puts restriction on the 
research since only a relatively small number of patients are studied. The genetic heterogeneity 
of cancer can be notably intriguing since differences are not only found between patients, but 
even between nodules in a single patient or with the same nodule (Bruix et al., 2014). For 
example, Tao et al. (2011) carried out whole genome sequencing where three nodules in the 
same patient were examined in one patient showing two driver mutations in a single nodule as a 
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result of clonal evolution and separate driver mutations in the other two nodules. Therefore, not 
only each patient represents a unique cancer signature, but every single tumor nodule might be 
genetically different from the other within the same individual. Another reason for the genetic 
variations in HCC is due to the etiology of the liver disease as well as the genetic background of 
the patient. Even when genetic research identifies oncogenic pathways there is usually several 
obstacles to target them therapeutically since the current pharmacological technology is more 
efficient in synthesizing kinase inhibitors than in preventing the protein-protein interactions. For 
example, despite the extensive research of the WNT/β-catenin pathways in HCC, they still 
represent several challenges to be pharmacologically targeted. The dependence of the cancer cell 
on the intrinsic oncogene mutation for survival is known as oncogene addiction; one of the aims 
of genetic research is to identify the oncogenic mutations necessary for therapeutic targeting. 
Due to the difficulty of cancer genetics, the progress that has been made in research so far is not 
yet enough to unveil the complexity of carcinogenesis in HCC (Sharma & Settleman, 2007). 
 Number of genome-wide association studies (GWAS) studying the single nucleotide 
polymorphisms have been carried out, where they identified the affected pathways, such as, 
inflammation-cytokine-chemokine systems, oxidative stress and detoxifying pathways, iron 
metabolism, DNA synthesis and repair mechanisms. It has been shown that functional 
polymorphisms in the epidermal growth factor receptor (EGFR) is associated with an increased 
risk of HCC (Chan et al., 2011; Nahon & Zucman-Rossi, 2012). In addition, somatic mutations 
activating telomerase reverse transcriptase promoter have been identified in the cirrhotic 
preneoplastic macronodules and early stages of HCC, which implicates that these mutations in 
the liver tissue could be used a diagnostic tool for HCC to identify high risk individuals (Bruix et 
al., 2014).  
 As a matter of fact, one of the main obstacles towards HCC treatment is its high risk of 
recurrence. Expression profiling studies of HCC tissue as well as the non-tumor tissue has 
provided insight into the high recurrence risk as well as predicted the recurrence of the tumor. 
Such data showed that the majority of tumor recurrences in the post curative therapy has not 
metastasized from the original tumor but are actually new tumors originating in the cirrhotic 
liver. Additionally, another known risk factor for recurrence of HCC is microinvasion, which 
entails that the genetic signature predicting vascular invasion would help in determining the 
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patient’s risk of recurrence. Currently the alternative approach to predict the recurrence of HCC 
has been combining pathological, clinical, and gene expression data (Villanueva et al., 2011). A 
study by Nault et al. (2013) showed that the combination of the proliferative molecular 
expression signature and the pathological data of the satellite nodules could be used to efficiently 
predict the recurrence of the disease.  
 Several studies focused on mRNA expression and genome-wide methylation profiling, in 
which three main pathways were identified, WNT/β-catenin, a proliferation and a 
hepatoblastoma-like pathway. However, the molecular signatures that have been identified so far 
are general and do not overlap with other studies. Thus, although they are informative there is a 
very small chance that they would be helpful in clinical practice, especially that they have not 
explained specific and targetable oncogenic pathways. Also, same scenario applies to the 
genome-wide methylation profiles that have been published so far (Shen et al., 2012). Another 
approach in the molecular classification of HCC is through analyzing the expression patterns of 
miRNA, which showed dysregulation of different miRNAs. However, no functional studies have 
been carried out to illustrate the nature of the miRNA dysregulation (Bruix et al., 2014).  
 
Figure 5. Worldwide liver cancer incidence in 2008. Age-standardized incidence of liver cancer rates in different 
parts of the world in 2008 according to the International Agency for Research on Cancer, the 2008 GLOBOCAN 
report. Adapted with permission from Dhanasekaran et al., 2012.    
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Figure 6. Incidence of liver cancer among in Egypt. The age specific incidence of liver cancer in Egypt 2008-
2011. Adapted from Ibrahim, Khaled, Nabiel, Baraka, & Kamel, 2014, open access article, no permission.    
H. HCC Diagnosis: 
Despite the recent advances in treatment options for liver cancer, the survival rate still 
remains very poor among the majority of liver cancer patients especially those presented at a 
relatively late stage of the disease (van Meer et al., 2013). Screening of high risk patients who 
suffer from chronic liver disease might help in detecting HCC at early stages, hopefully leading 
to decreased mortality rate. However, surveillance and screening remain controversial due to the 
limited evidence available regarding their efficiency, sensitivity, and the potential risk factors 
(Lederle & Pocha, 2012; Sherman, Bruix, Porayko, & Tran, 2012). Therefore, new screening 
strategies are urgently needed in order to tackle severity of HCC.  
In order to lower the incidence of HCC, diagnose it early, and establish an efficient 
epidemiology, both proper screening and surveillance should be applied (Noda et al., 2010). 
Screening is running a particular test in order to detect a disease in a population that show no 
symptoms or signs of that diseases, while surveillance is periodically repeating that screening 
test on the same target population. The main goal of both screening and surveillance is to detect a 
certain disease before it starts becoming symptomatic, when treatment would be more effective, 
ultimately decreasing the disease mortality. In case of positive results of screening or 
surveillance tests there must be a clear protocol to identify true positive cases with a specific 
diagnostic plan (Giannini et al., 2013).   
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i. Screening and Surveillance Guidelines: 
The aim of surveillance for HCC is to detect small lesions that will respond to curative 
treatments and hence improve patient overall survival. One of the main guidelines for successful 
screening and surveillance is the disease being common with significant morbidity and mortality 
(Giannini et al., 2013). HCC is a very common malignancy worldwide, where its incidence is 
expected to increase in Western countries as a result of the aging of patients suffering from 
chronic HCV, which remains as the major etiological factor of HCC in the developed world (El-
Serag, 2004 & Kanwal et al., 2011). It has been shown that the rates of incidence and mortality 
are quite similar worldwide, therefore demonstrating the short term lethality of this tumor 
especially when diagnosed at late stages of the disease hindering methods of effective treatment. 
Also for a screening and surveillance program to be successful the target population must be 
easily identifiable (Bosetti et al., 2008; Bosetti et al., 2009; & Bertuccio et al., 2013). As 
mentioned before about 90% or more of all HCC patients progress from a cirrhotic liver, which 
is mainly caused by chronic liver diseases such as HBV and HCV, alcoholism, and non-alcoholic 
fatty liver disease. These liver diseases can be diagnosed using the patient history and/or 
serological tests, which would easily identify patients at risk of HCC and in need of surveillance 
(Fattovich, Stroffolini, Zagni, & Donato, 2004). 
 Characteristics such as low morbidity, high sensitivity and specificity are critical 
components of surveillance. According to the American and European guidelines for 
management of HCC, it is recommended that surveillance should be done by a liver ultrasound 
examination every 6 months. Such periodical surveillance is expected to have no morbidity, 
since when the ultrasound is carried out properly it has a relatively high specificity and 
sensitivity (Bruix & Sherman, 2011; European Association for The Study Of The Liver, 2012). 
In a meta-regression analysis by Singal et al. (2009), it was shown that ultrasound has the ability 
to detect subclinical HCCs with a 94%-95% sensitivity; however, the sensitivity is only 63% for 
early HCC detection, while the specificity was usually more than 90%. A semiannual ultrasound 
is considered an easy non-invasive procedure that is relatively low cost, which makes it possible 
for the patient to follow (Davila et al., 2010). Therefore, the demand is high for skillful 
sonographers to perform a reliable HCC surveillance using ultrasound. Additionally, serum 
alpha-fetoprotein (AFP) has been used as a surveillance tool with an acceptable specificity; 
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however, it has a low sensitivity for early HCC detection since only 10-20% of early 
malignancies is presented with high levels of serum AFP. Combining ultrasound and serum AFP 
shows slight increase in sensitivity of the surveillance test; however, it doubles the cost because 
of the high number of false positives. In Europe and the United States, it is recommended that 
patients with a HCC high risk like those suffering from cirrhosis and/or chronic hepatitis, 
undergo periodical surveillance (Trevisani et al., 2002; Bruix & Sherman, 2011; Sherman, 2011; 
European Association for The Study Of The Liver, 2012; & Giannini et al., 2012).  
ii. Biomarkers for HCC Screening: 
        The screening for HCC at the advanced or intermediate stage of the disease [according to 
the system of the Barcelona Clinic Liver Cancer Staging (BCLC)] could have a great 
significance for the TACE or sorafenib therapy. However, screening should be better in detecting 
the disease at its very early stages (one lesion ≤ 5 cm or 3 lesions each ≤ 3 cm with no metastasis 
or angiogenesis), and therefore allowing a better opportunity for potential curative therapy (van 
Meer et al., 2013). The serological biomarkers are considered cost effective and less physical 
burden for the patient. Many serological biomarkers have been investigated for early detection of 
HCC, usually for diagnostic purposes rather than surveillance and screening studies. For 
decades, AFP has been the most commonly used serological biomarker for HCC detection (van 
Meer et al., 2013).  
Alpha-fetoprotein is a glycoprotein expressed in the fetal hepatocytes or malignant HCC 
cells. However, AFP is not secreted into the circulation by all HCC cells; in addition, the levels 
of AFP have been shown to be elevated in chronic liver disease patients without HCC as well as 
in patients with other types of malignancies (Di Bisceglie et al., 2005). According to a report 
published by Gupta et al. (2003) studying patients with HCC at all stages of the disease with an 
underlying cirrhotic or non-cirrhotica HCV, AFP remains a weak biomarker for screening even 
with the highest sensitivity and specificity estimates. With the usual AFP cut-off of 20 ng/ mL, 
the sensitivity and specificity for HCC detection were 41%-65% and 80%-94%, respectively 
(Gupta et al., 2003). A recent large case-control study was performed that included 419 HCC 
cases and 417 cirrhotic controls with different etiologies, in which the efficiency of AFP in early 
HCC detection was compared with other serological biomarkers, such as lectin-bound AFP and 
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des-carboxyprothrombin (DCP) (Marrero et al., 2009). In this study, AFP sensitivity and 
specificity for early detection of HCC were 53% and 90%, respectively, using 20 ng/ mL as the 
recommended clinical cut-off point. In the receiver operating characteristics (ROC) curve a point 
with ideal sensitivity and specificity was used as cut-off of 10.9 ng/ mL, in which the sensitivity 
turned out to be 66% while specificity was 82%. This finding suggested that the usual cut-off 
point of 20 ng/ mL is too high for the optimum AFP screening (Marrero et al., 2009).    
Lectin-bound AFP is another potential serological biomarker for early detection of HCC. 
Lectin-bound AFP, is one of the three glycoforms of AFP, demonstrated by its reactivity in lectin 
affinity electrophoresis (Li, Mallory, & Satomura, 2001). A study investigated the accuracy in 
diagnosis comparing lectin-bound AFP and AFP in patients suffering from cirrhosis as a result of 
an HCV infection (Sterling et al., 2007). The incidence of HCC at reference point and during a 
two years was much higher in patients with high levels of lectin-bound AFP than patients with 
high AFP. In addition, patients with elevated AFP levels had higher levels of lectin-bound AFP, 
which suggests that the levels of lectin-bound AFP has clinical importance as another test for 
HCV patients with low AFP levels by categorizing a subgroup of patients with a high chance of 
HCC (Sterling et al., 2007). Other studies have reported even less encouraging results regarding 
the accuracy and efficiency of lectin-bound AFP. Numerous of studies have investigated the 
diagnostic efficiency of a combination of serological biomarkers; however, when AFP and DCP 
were combined there seemed to be little or no progress in the rates of sensitivity for early HCC 
detection (van Meer et al., 2013).      
 DCP is an abnormal protein produced as a result of a defect that is acquired during the 
post-transitional carboxylation of the prothrombin precursor in cancerous hepatocytes (Liebman, 
1989). Several studies have investigated the efficiency of DCP as a serological biomarker for 
early detection of HCC; however, the results were inconclusive (Ishii et al., 2000; Ikoma et al., 
2002; Marrero et al., 2003; & Lok et al., 2010). For example, a case-control study with 39 HCC 
cases and 77 controls, DCP was shown to be more accurate than AFP (Lok et al., 2010). DCP 
alone has sensitivity and specificity of 74% and 86%, respectively, with a cut-off value of 40 
mAU/ mL (Marrero et al., 2009).   
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 Recent studies have suggested new serum biomarkers for early HCC detection, such as 
the receptor of angiopoietins tyrosine kinase with Ig (immunoglobulin) and EGF (epidermal 
growth factor) homology domains 2 (TIE2). TIE2 expressing monocytes (TEMs) were recently 
discovered to be enriched in HCC as well as in other tumors where angiogenesis is essential for 
tumor development (van Meer et al., 2013). According to Matsubara et al. (2013) in a study that 
included 168 HCV patients, of which 89 had developed HCC registered a significantly higher 
abundance of TEMs in the peripheral blood independent of the tumor stage. TEMs were also 
elevated in a separate group of HCC patients without HCV. TEMs were more effective than AFP 
and DCP in discriminating HCC from cirrhosis or chronic hepatitis (Matsubara et al., 2013). On 
the other hand, it was shown in another study that circulating and intrahepatic TEMs were 
elevated in patients who did not develop HCC but had HCV infection (Rodríguez-Muñoz et al., 
2011). Although these findings represent a limited cohort of HCV-infected patients, they still 
might indicate that TEMs expansion and mobilization may not be strictly HCC related, but 
associated more with chronic liver infection (De Palma, Coukos, & Semela, 2013).  
Other research groups studied the role of Glypican-3 (GPC3), which is a surface protein 
expressed in the majority of HCC cases, yet it is undetectable in the hepatocytes of normal 
individuals as well as patients who are presented with a benign liver disease (Capurro et al., 
2003; Tangkijvanich et al., 2010; & Yasuda et al., 2010). Golgi protein 73 (GP73) is another 
potential biomarker, which is an amino acid that is usually found in the Golgi complex (van 
Meer et al., 2013). Marrero et al. (2015) showed that the levels of GP73 are elevated in the 
serum of HCC patients, with a 62% sensitivity for early detection of HCC.  
Interleukin-6 (IL-6) a cytokine associated with cell differentiation and growth, is another 
potential biomarker for HCC that has been investigated. The concentrations of serum IL-6 
appeared to be elevated in HCC patients compared to healthy individuals (Hsia et al., 2007 & 
Porta et al., 2008). The sensitivities of IL-6 for the differentiation between HCC patients and 
healthy control ranged from 46% to 73%, while the specificities ranged from 87% to 95% 
(Giannelli et al., 2005 & Hussein et al., 2008). Although extensive research has been conducted 
aiming to uncover the most reliable HCC biomarkers that would help in the early diagnosis of 
the disease, there is still a lot of work that needs to be done in order to discover the most specific, 
sensitive, non-invasive biomarker for HCC diagnosis. 
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iii. Imaging Techniques for HCC Screening: 
Currently, the most commonly used method for surveillance of HCC is ultrasonography 
(US). The main advantage of US is the lack of invasiveness; however, it is known to be time-
consuming, technician-dependent, and relatively expensive (van Meer et al., 2013). In addition, 
the method is not applicable for an overweight patient. It was shown in a meta-analysis by Singal 
et al. (2009) with 13 studies included, that the combined sensitivities and specificities were 94% 
for HCC detection at any stage. On the other hand, US was less accurate in detecting the 
potentially curable early stages of HCC, in which the combined sensitivity was 63%. Another 
systematic study by Colli et al. (2006) showed that US alone is inadequately sensitive for HCC 
screening. According to this study, sensitivities for HCC detection (all disease stages combined) 
in the 14 studies included, ranged from 30%-100%, while specificities ranged from 73%-100%. 
However, it is important to take note that noticeable variability between the studies can be due to 
the populations tested, the size of the tumors, and/or differences in technicians’ experience and 
skills. Additionally, Singal et al. (2009) studied combining AFP with US in a meta-analysis 
aiming at the early detection of HCC. There was a slight increase in the pooled sensitivities from 
63% to 69%; however, it was not statistically significant, which suggests that combining AFP 
with US is not very effective in HCC screening (van Meer et al., 2013). Clinical evidence 
suggests that the interval of tumor growth from undetectable to a lesion of 2 cm in diameter 
usually ranges from 4 to 12 months.  
Recently, computed tomography (CT) and magnetic resonance imaging (MRI) are now 
being used as good tools for HCC screening. However, these imaging techniques are mainly still 
used to further evaluate cases with abnormal findings from US results in order to determine the 
extent of the tumor. According to a comprehensive review by Colli et al. (2006), spiral CT 
imaging showed comparable sensitivities and specificities similar to US for HCC detection in 
patients presented with chronic liver disease. The combined sensitivities for US and spiral CT 
imaging were 60% and 68%, respectively, while the combined specificities were 97% and 93%, 
respectively (Colli et al., 2006).                           
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I. MicroRNAs and HCC: 
 MicroRNAs have been associated with the regulation of cellular processes that are known 
to be deregulated in cancer, such as proliferation, apoptosis, and differentiation. Changes in the 
expression of miRNAs in cancer have been demonstrated in several studies, suggesting the 
significant contribution of miRNAs to the characteristics of the tumor cells (Hermeking, 2010). 
Additionally, several miRNA-encoding genes have been categorized as either tumor suppressive 
or oncogenic according to the role they play during cell transformation and altered expression in 
cancers. MicroRNAs with tumor suppressive ability may act by downregulating the proto-
oncogenes products, such as in the case of miRNA family let-7 that targets the expression of 
KRAS, HMGA2, and NRAS oncogenes, and it is not expressed in lung tumors (Hermeking, 2010).  
i. MiR-34a: 
 The role of miR-34a has been frequently studied, which revealed its significant role in 
development of carcinogenesis in many different cancers. In HCC, miR-34a is known to inhibit 
the invasion and migration of the human HCC cells (Li et al., 2014). In a study by Li et al. 
(2009), the research group highlighted the important role miR-34a plays in regulating the 
scattering, migration, and invasion of tumor cells. In the study, 19 out of the 25 (76%) HCC 
human tissue samples showed down-regulation of miR-34a in comparison to adjacent normal 
tissue (Li et al., 2009). Additionally, normal and HCC tumor tissues of 25 patients showed an 
inverse correlation between the c-Met-protein and miR-34a. In HepG2 cells, the ectopic 
expression of miR-34a significantly inhibited the migration and invasion of tumor cells in a c-
Met-dependent manner (Li et al., 2009; Dang et al., 2013). Several studies back in 2007, 
reported that members of the miR-34 family are considered direct targets of p53, in which their 
upregulation is seen to induce cell-cycle arrest and apoptosis (Figure 7). In mammals, the miR-34 
family includes three mature miRNAs encoded by two different genes, in which miR-34a is 
encoded by its transcript, while miR-34b and miR-34c have the same common primary transcript 
(Figure 8) (Hermeking, 2010). In mice, miR-34a is abundantly expressed, where the brain tissue 
shows the highest expression, while miR-34b/c is highly expressed in the lungs. Recent studies 
demonstrated that the expression levels of miR-34a are higher than miR-34b/c, except for the 
lungs where miR-34b/c is mainly expressed. Thus, the two miR-34 genes are considered to have 
tissue-specific functions (Bommer et al., 2007). It was shown that miR-34 genes show liver 
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ectopic expression, which has significant impact on cellular proliferation and survival. For 
example, the ectopic expression of miR-34a and miR-34b/c induced cell-cycle arrest at the G1 
phase. Both proliferation and colony formation was inhibited in soft agar due to the expression of 
miR-34b/c. Several studies also showed that the re-expression of miR-34a induced apoptosis, and 
since apoptosis and cell-cycle arrest usually occur upon the activation of p53, it is hypothesized 
that miR-34 genes may act as effective mediators of p53 tumor suppression (Chang et al., 2007). 
The tumor suppressor protein, p53, is a transcription factor responsible for regulating stress 
response genes as well as facilitating different anti-proliferative processes (Vogelstein et al., 
2000). As a matter of fact, a number of p53 tumor suppressor functions are regulated by 
miRNAs. In 2007, more than one research group have shown that the members of the miR-34 
family are the most commonly p53-induced miRNAs (Bommer et al., 2007; Chang et al., 2007; 
He et al., 2007; Raver-Shapira et al., 2007). After that several studies demonstrated that the miR-
34 family members are crucial mediators of tumor suppression. Members of the miR-34 family 
have been associated with the regulation of different cancer-related processes, such as epithelial 
to mesenchymal transition (EMT), proliferation, migration, apoptosis, metastasis, and invasion 
(Figure 9) (Rokavec et al., 2014). Microarray analyses revealed that after the ectopic 
introduction of various members of the miR-34 family into different cell lines hundreds of miR-
34 targets were downregulated. It was revealed that mRNAs that function in cell-cycle control as 
well as the DNA damage response were among the majority of transcripts found to be 
downregulated by the miR-34 family. In addition, these downregulated mRNAs revealed an 
enrichment of miR-34 seed-matching sequences in their 3’-UTR regions (Hermeking, 2010).    
 MiR-34a is a highly conserved miRNA, which is recently identified as a significant tumor 
suppressor in a number of malignancies through its suppression of multiple targets (Li et al., 
2014). MiR-34a expression can mainly be regulated through epigenetic modification, genomic 
loss, and transcriptional regulation (Figure 10). MiR-34a is encoded on the distal region of 
chromosome 1p, where it has been reported that genomic loss of this particular region is found in 
different malignancies; thus, the loss of the miR-34a gene that acts as a tumor suppressor is 
logical. Although the mechanism through which miR-34a is dysregulated in human malignancies 
is not well understood yet, there remains substantial evidence suggesting that epigenetic changes 
are involved in the process of carcinogenesis (Nagai, Negrini, Carter, Gillum, Rosenberg, 1995; 
Attiyeh et al., 2005; Zhang et al., 2010).  
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Transcriptional silencing through the methylation of CpG islands is considered one of the 
most significant processes through which tumor suppressor genes are inactivated. In addition, 
inactivation by CpG methylation can result in clonal growth with a selective advantage during 
tumorigenesis (Li et al., 2014). Silenced expression of miR-34a has been reported in a number of 
malignancies, such as colon, breast, lung, bladder, kidney, pancreatic cancers due to the 
hypermethylation of CpG islands in the miR-34a gene promoter region. Additionally, upon 
treatment with DNA methyltransferase inhibitor, 5-aza-2’deoxycytidine, there was a decline in 
CpG methylation of miR-34a, leading to the reactivation of the miR-34a gene. The promoter 
region far away from the transcription start site was analyzed to reveal that it contains uniformly 
increased CpG methylation. Thus, silencing the expression of miR-34a is believed to be 
facilitated by CpG methylation of a certain region 100-500 base-pairs upstream of the 
transcription start of miR-34a (Lodygin et al., 2008).  
 The expression of miR-34a is regulated by multiple transcription factors, such as ETS-
like protein 1, which was shown to increase the miR-34a expression (Antonini et al., 2010). MiR-
34a is negatively regulated by a member of the p53 family; p63, which is associated with the 
progression of the cell cycle through the direct repression of miR-34a transcription. When p63 is 
absent, it was observed that the levels of miR-34a were elevated in epidermal cell through the 
direct binding to p53-consensus sites in the regulatory regions of miR-34a, thus inhibiting its 
activity (Siemens et al., 2011).  
 As the functions of miRNAs in human diseases are being gradually understood, several 
research groups are currently investigating the role of miRNAs in cancer therapy. Generally, 
upregulation of miRNAs occurs through the administration of synthetic miRNAs or miRNA-
expressing vectors. On the other hand, miRNAs are downregulated through the addition of anti-
sense nucleotides. It has been observed that in the majority of tumors, the levels of miR-34a are 
downregulated, which categorizes this miRNA as a tumor suppressor. The significance of miR-
34a is evident by the numerous factors responsible for its regulation. This complicated network 
of regulatory mechanisms and transcription factors lead to miR-34a’s tissue-specific expression 
in various types of tumors (Li et al., 2014). 
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Figure 7. The miR-34 family as a facilitator of tumor suppression by p53. After double-strand breaks take place, 
p53 gets activated through ATM-kinases and transactivates other target genes through consensus binding sites. 
Primary transcripts of the activated miR-34 genes are then processed by DROSHA and DICER complexes. After 
that the mature miRNA is incorporated in the RISC complex to either inhibit translation or degrade RNA of specific 
targets. Adapted with permission from Hermeking, 2010. 
 
 
Figure 8. A detailed structure of the genomic loci of human miR-34a and miR-34b/c genes. The white boxes 
represent exons, while the miRNA hairpins are represented by the black boxes. The hatched boxes represent the 
p53-binding sites, whereas the thick black lines indicate the CpG islands location Adapted with permission from 
Hermeking, 2010. 
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Figure 9. miR-34 regulation in cancer. The regulation of multiple cancer-related processes and pathways by the 
miR-34 family through the targeting of key factors. Down-regulated proteins due to miR-34 direct targeting are 
grouped according to their function. The net regulation effect of miR-34 on each pathway is shown by a green 
arrow (activation) or a red inhibitory sign. Adapted with permission from Rokavec et al., 2014.  
 
39 
 
 
Figure 10. miR-34a regulation. A diagram showing the means through which the expression of miR-34a is 
regulated. Inhibition is indicated by the red arrows, while green arrows represent activation. Adapted with 
permission from Li et al., 2014.                       
ii. MiR-221:  
MiR-221/222 are homologous highly conserved miRNAs in vertebrates encoded in 
tandem on the X chromosome, in which they act as tumor promoters due to their upregulation in 
human malignancies (Di Martino et al., 2016). Number of studies have shown the role miR-
221/222 play in tumor development either as an oncomiR or oncosuppressor-miRs (Garofalo et 
al., 2012).  MiR-221 was shown to be overexpressed in human cancers, such as glioblastoma, 
breast cancer, and colorectal cancer. Additionally, it was recently reported that miR-221 
stimulates the onset of tumorigenesis and promotes the progression of the tumor, hence 
shortening the lifespan of mouse models with liver cancer (Li et al., 2011). In 2007, Galardi et 
al. (2007), discovered the cell cycle regulator, p27Kip1, as the target for the miR-221/miR-222 
family. They demonstrated that in pancreatic cells, the expression levels of p27Kip1 and miR-
221/miR-222 are inversely correlated, and showed that overexpression of miR-221/222 
significantly affected proliferation and the distribution of the cell cycle phase. These findings 
were then confirmed in thyroid papillary carcinomas, breast cancer, glioblastomas, lung cancer, 
and hepatocellular carcinoma.  
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A study by Li et al. (2011) revealed that in the 46 HCC samples tested, miR-221 was 
significantly elevated in the sera of 35 samples compared to the normal controls. Additionally, it 
was shown that the significant upregulation of miR-221 was directly correlated with the size of 
the tumor, tumor stage, and cirrhosis. Also, it was observed that the expression of miR-221 
increases as the TNM (Classification of Malignant Tumors) stage progresses (Figure 11) (Li et 
al., 2011). However, no correlation has been established between the expression of miR-221 and 
other clinical factors, such as gender, age, HBV infection, and alcohol abuse. It was concluded 
that, the more advanced the tumor, the more up-regulated miR-221 expression is, and hence the 
expression of miR-221 could directly affect the patients’ prognosis. As shown in Figure 12, the 
overall survival rate of HCC patients with high miR-221 expression is significantly lower 
compared to patients with low miR-221 expression (Li et al., 2011).    
Another study by Pineau et al. demonstrated that the dysregulation of miR-221 is 
associated with the progression of liver tumorigenesis, in which they function through the 
targeting of CDK inhibitors p27 and p57 at the protein level. It was concluded that the 
expression profiles of certain miRNAs change during the progression of liver tumorigenesis, in 
which some act as real oncomiRs, such as miR-221 (Pineau et al., 2010). Additionally, Fornari et 
al. (2008) showed that CDKN1C/p57 is a direct target of miR-221 in the liver, proving further 
the oncogenic function of miR-221 in hepatocarcinogenesis. As expected, the transfection of 
miR-221 in Hep3B cells resulted in 1.8-fold decrease of CDKN1C/p57, while the transfection of 
SNU449 cells with antimiR-221 there was a 1.3-fold increase in the protein levels of 
CDKN1C/p57 when compared to negative control miRNA inhibitors (Garofalo et al., 2012). 
In another study, patients with chronic HCV infection had elevated levels of miR-122a 
expression as well as AST and ALT, which were positively correlated with the upregulation of 
miR-221. The elevated levels of miR-221 may reflect the liver damage caused during the course 
of the chronic HCV infection; and thus, the levels of circulating miR-221 can be an indicator of 
the disease activity (Ding et al., 2015). This study showed the significant upregulation of miR-
221 in the serum of chronic HCV patients, which is suggested to be through the association of 
miR-221 with the NF-κB cascade. Several studies have demonstrated the activation of NF-κB-
dependent inflammatory pathways in chronic viral hepatitis, cirrhosis, and HCC (Figure 13). NF-
κB has a binding site at the promoter region of miR-221, in which the upregulation of miR-221 
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could be completely blocked by NF-κB inhibitor (PDTC), suggesting that the upregulation of 
miR-221 during HCV infection occurs in a NF-κB dependent manner (Ding et al., 2015). 
 
 
Figure 11. MiR-221 Expression. MiR-221 expression pattern in normal controls compared to different clinical 
stages of HCC serum samples. Significant differences were evident between the different groups (p < 0.05). 
Adapted with permission from Li et al., 2011. 
 
Figure 12. Kaplan-Meier survival curves of HCC patients. The 5-year overall survival rate of HCC patients 
with high serum expression of miR-221 was considerably lower compared to HCC patients with low expression of 
miR-221. Adapted with permission from Li et al., 2011. 
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Figure 13. MiR-221 Regulation. The regulatory mechanisms of the miR-221/222 family in hepatocarcinogenesis. 
Adapted from Matsuzaki & Suzuki, 2015, open access article, no permission.    
iii. MiR-199a: 
MiR-199a is located on chromosome 19 in the dynamin-2 gene within intron 14. MiR-
199a is one of the most highly expressed miRNAs in the normal liver (Song et al., 2014). Several 
studies have shown that the expression on miR-199a is down-regulated in several types of 
cancer, including HCC. MiR-199a was shown to be down-regulated in prostate, ovarian, colon, 
renal, bladder cancers, and oral squamous cell carcinoma, while it was up-regulated in gastric 
cancer, bronchial squamous cell carcinoma, and cervical carcinoma (Song et al., 2014). In a 
study by Li et al. (2016), systematic analysis revealed that miR-199a is significantly decreased in 
HCC cases, and hence it functions as a tumor suppressor through the inhibition of the 
oncogenesis thus preventing tumor development. As a tumor suppressor, miR-199a was shown 
to negatively regulate cMet, which is an important oncogene that plays a role in invasion and 
metastasis of HCC. Therefore, in HCC cell lines it was shown that overexpression of miR-199a 
decreases invasion and proliferation. Moreover, in gastric cancer, miR-199a is known to regulate 
the tumor suppressor mitogen-activated protein kinase kinase kinase 11 (Li et al., 2016). In 
another by study by Song et al. (2014), qRT-PCR results demonstrated that miR-199a is 
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involved in the regulation of human hepato-carcinogenesis, in which its expression levels were 
decreased by 82.5% in HCC tissues compared adjacent non-neoplastic liver tissue. Additionally, 
the cell line expression displayed a similar pattern to that found in tissues. Further analysis also 
revealed that the low expression of miR199a correlated with worse HCC patients’ prognosis, in 
which clinical features analysis of 40 HCC patients showed decreased expression of miR-199a in 
association with the TNM stage of patients and tumor metastasis. After that, survival analysis 
revealed that the down-regulation of miR-199a was significantly correlated with poor prognosis 
for HCC patients (Song et al., 2014).  
The members of the miR-199 family include, miR-199a-5p, miR-199a-3p, and miR-
199b, which are all known to be down-regulated in HCV-induced HCC cases when compared to 
healthy controls and cases with post-hepatitis cirrhosis and liver failure (El-Abd et al., 2015). 
The strong association of miR-199a/b with HCC, regardless of the etiology, is very evident in all 
expression analysis profiles especially that it the third most highly expressed miRNA in liver 
tissue (Diaz et al., 2013). The expression of miR-199a/b has always been down-regulated in 
HCC patients with different etiologies, such as HBV, HCV, and high alcohol consumption. As 
previously mentioned, the strong correlation between HCC and miR-199a/b has been 
demonstrated through the poor rate of survival, short time to tumor recurrence, growth inhibition 
of HCC in vivo and in vitro following administration of miR-199a/b, and the down-regulation of 
tumor-promoting pathways such as mTOR, c-MET, and PAK4/Raf/MERK/ERK (Diaz et al., 
2013).   
iv. MiR-16: 
  In 2002, Calin et al. demonstrated that miR-16 is located within a small region of the 
13q14 chromosome, which was found to be deleted in more than 65% of chronic lymphocytic 
leukemia (CLL) cases. Their study showed that allelic loss in this chromosomal region is 
associated with the down-regulation of miR-15 and miR-16 suggesting that these genes are 
inactivation targets by allelic loss found in CLL, which was one of the first pieces of evidence to 
suggest the importance of miRNA genes in tumorigenesis. The mapping of the miR-15a and 
miR-16-1 genes in a region usually altered in cancer served as evidence that these two miRNAs 
could be the 13q14.3 target genes. Number of studies of CLL as well as solid tumors have 
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demonstrated the deletion or down-regulation of miR-15a and miR-16-1 in malignant cells, 
implicating that these two miRNAs could be ‘hot spots’ in tumor transformation (Calin & Croce, 
2006). Expression analysis of miR-15a and miR-16-1 in prostate cancer showed consistent down-
regulation of these two genes in approximately 80% of tumor tissue samples compared to that of 
normal tissues. Additionally, no association has been reported between the loss of RB, which is 
located in the same area, and the down-regulation of miR-15a and miR-16-1, thus suggesting that 
miR-15a and miR-16-1 down-regulation or loss is independent of the absence of the RB encoding 
gene (Figure 14). Additionally, lower expression of miR-15a and miR-16-1 was shown in 
pituitary adenomas compared to normal pituitary tissues. Collectively, these data suggested that 
miR-15a and miR-16-1 function as tumor suppressors where their inactivation by allelic loss 
contributes to carcinogenesis (Bottoni et al., 2005).    
 It was found that the sequences of miR-15a and miR-16-1 and the BCL2 mRNA have a 
complementary homology, hence suggesting that the oncoprotein Bcl2 might be a post-
transcriptional repression target by the tumor suppressors, miR-15a and miR-16-1 (Cimmino et 
al., 2005). Bcl2 has a critical role in the eukaryotic cell genetic program, in which it favors 
survival through cell death inhibition. Therefore, the up-regulation of Bcl2 has been shown in 
several types of human tumors, such as carcinomas, leukemias, and lymphomas (Figure 14) 
(Sanchez-Beato, Sanchez-Aguilera, & Piris, 2003). In a study by Qu et al. (2011), where they 
investigated the expression levels of liver-specific miRNAs in the sera of HCC patients and 
chronic liver disease (CLD) patients, the data revealed that the serum levels of miR-16 were 
noticeably lower in HCC patients compared to CLD and normal individuals. As a matter of fact, 
miR-16 was identified in 76 out of 105 HCC patients, which as a single marker had the highest 
sensitivity of all other miRNAs investigated. Additionally, combining miR-16 with other 
conventional HCC biomarkers such as, AFP, AFP-L3, and DCP resulted in great diagnostic 
accuracy, with a specificity of 78.5% and sensitivity of 92.4% (Qu et al., 2011). Additionally, Qu 
et al., investigated the miRNA expression in the sera of patients with tumor size ≤ 3 cm, where 
miR-16 was identified in 34 out of the 43 patients with small tumor size, which was a more than 
the number identified with the conventional serum HCC markers (Qu et al., 2011). On the other 
hand, in another study by Tan et al., although miR-16 was significantly down-regulated in HCC 
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patients compared to the controls, yet it did not meet the candidate miRNA selection criteria set 
by the research team at the microarray level (Tan et al., 2014). 
 
Figure 14. MiR-16 Regulation. Through the regulation of Cdk4/6-cyclin D complexes and Cdk2-cyclin E 
complexes, the miR-16 family facilitates the G1/S transition. The transition of G1/S is mainly regulated by 2 
complexes, D-type cyclins with CDK4/CDK6 and E-type Cyclins with CDK2. The two complexes are responsible 
for the phosphorylation and inhibition of Rb and E2F binding, resulting in the activation of E2F-mediated 
transcription and transitioning the cells from the G1 to the S phase. The inactivation of Cdk2/4/6 as well as the 
expression levels of Cyclin E1, Cyclin D1, Cyclin D3, and CDK6 are controlled by the miR-16 family, and hence 
preventing the Rb proteins phosphorylation. Additionally, miR-16 is responsible for inducing apoptosis through 
the downregulation of Bcl-2, an anti-apoptotic protein. Adapted from Liu et al., 2008, open access article, no 
permission.    
v. MiR-122a: 
MiR-122a is undetectable in the majority of tissues, while it accounts for approximately 70% of 
the total liver microRNA population. MiR-122a has critical functions in the regulation of 
hepatocyte development, lipid metabolism, stress response, and differentiation (Nakao, Miyaaki, 
& Ichikawa, 2014). The expression of miR-122a is determined by liver-enriched transcription 
factors (LETFs), that also include hepatocyte nuclear factor (HNF) 4a and 6, that also regulates 
the dosage of miR-122a in vivo during liver development (Xu et al., 2010; Laudadio et al., 2012; 
Deng et al., 2014). As a matter of fact, during liver development, the increased expression of 
miR-122a and LETFs is believed to maintain the balance between cellular differentiation and 
proliferation in cholangiocyte and hepatocyte lineages. This sequential regulation of the 
expression of miR-122a is crucial since miR-122a plays a role in hepatobiliary segregation while 
maintaining a hepato-specific phenotype. In mouse models for liver development, miR-122a is 
responsible for the terminal liver differentiation through gradually repressing the transcription 
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factor cut-like homeobox 1 (CULT1) (Figure 10) (Xu et al., 2010). The function of miR-122a in 
liver development and differentiation was studied further by demonstrating that miR-122a 
antisense-mediated inhibition delayed the development of the liver in zebrafish models, and 
resulted in the expression of suppressed genes in the liver of adult mouse models. Additionally, 
this was proven further by that fact that in primary HCC with poor prognosis, miR-122a 
repression was associated with hepatic phenotype suppression (Krützfeldt et al., 2005; 
Coulouarn, Factor, Andersen, Durkin, & Thorgeirsson, 2009).       
In the case of liver disease, the use of germline knock-out (KO) mice and liver-specific KO 
mice has been extremely helpful in demonstrating the key role miR-122a plays in the 
development and progression of liver disease (Bandiera et al., 2015). It was demonstrated that 
the genetic loss of miR-122a not only severely impacts lipid metabolism, but initiates 
inflammation and microsteatosis that led to the development of steatohepatitis and fibrosis as the 
mice got older. Additionally, carbon tetrachloride-induced mouse model of liver fibrosis showed 
a low expression of miR-122a (Hsu et al., 2012; Tsai et al., 2012). As a matter of fact, restoring 
the levels of miR-122a in miR-122a KO mice caused liver inflammation to be partially reversed, 
through the repression of miR-122a targets, the chemokine Ccl2 responsible for the intrahepatic 
recruitment of CD11bhiGr1+ inflammatory cells, and the pro-fibrogenic Krüppel-like factor 6 
(KLF6) that is up-regulated in the miR-122a KO mouse liver. These findings demonstrated 
clearly the anti-fibrotic and anti-inflammatory functions of miR-122a in the liver (Hsu et al., 
2012; Tsai et al., 2012).  
MiR-122a stimulates the replication of HCV through the direct binding to the HCV RNA on 
the HCV 5’UTR, while it inhibits HBV replication through the p53-mediated inhibition of HBV 
transcription. MiR-122a functions as a tumor suppressor as it inhibits the development of HCC 
through binding to target genes responsible for HCC cellular proliferation, differentiation, 
migration, angiogenesis, and apoptosis (Nakao, Miyaaki, & Ichikawa, 2014). It has been reported 
in several studies that miR-122a is down-regulated in HCC tissue in comparison to adjacent 
normal tissue, in which loss of miR-122a expression has been associated with HCC metastasis 
and poor prognosis. Coulouarn et al. (2009) reported that in HCC tissue, loss of expression was 
associated with low apoptotic index and high proliferation. MiR-122a down-regulation has also 
been observed in several HCC human cell lines, even though the miR-122a expression levels 
vary with more than 1000-fold differences among various cell lines (Coulouarn et al., 2009).   
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MiR-122a serum expression levels have been studied in patients with HCC as well as other 
chronic liver diseases (Nakao, Miyaaki, & Ichikawa, 2014). The miR-122a serum levels were not 
significantly different between HCC patients compared to patients without HCC; however, they 
correlated positively with liver transaminases and were negatively correlated with the Model for 
End-Stage Liver Disease (MELD) score, which indicates that circulating serum miR-122a is a 
reliable biomarker for liver injury but not necessarily for HCC (Nakao, Miyaaki, & Ichikawa, 
2014).      
Several research groups have identified different target genes of miR-122a that play a role in 
hepatocarcinogenesis and epithelial mesenchymal transition (EMT). For example, the expression 
of cyclin G1 is directly down-regulated by miR-122a, resulting in an inverse relationship 
between the expression of cyclin G1 and miR-122a in HCC tissue (Gramantieri et al., 2007). 
Deregulation of cyclin G1 has been shown to be associated with genomic instability, where the 
over-expression of cyclin G1 has been demonstrated in leiomyoma, breast, and colorectal cancer. 
Additionally, laboratory evidence from cancer cell lines and tumor xenografts demonstrated that 
loss of cyclin G1 leads to tumor growth inhibition by decreasing proliferation and inducing 
apoptosis. For example, in experimental hepatocarcinogenesis, loss of cyclin G1 is correlated 
with a noticeably low tumor incidence following a carcinogenic incident, in which cyclin G1-
null hepatocytes enter the S phase at a slower rate (Gramantieri et al., 2007). MiR-122a is also 
known to up-regulate the p53 expression and its transcriptional functions through the negative 
regulation of cyclin G1 of p53 protein’s stability that acts on the B’ subunit of phosphatase 2A 
(Nakao, Miyaaki, & Ichikawa, 2014).    
Finally, the down-regulation of miR-122a was shown to be associated with poor prognosis 
and liver cancer metastasis. Additionally, number of miR-122a targets have been shown to be 
associated with tumorigenesis, such as cyclin G1, ADAM10, IGF1R, SRF, and Wnt1, in which 
they contribute to hepatocarcinogenesis, angiogenesis, and epithelial-mesenchymal transition 
(Bandiera et al., 2015). All these data compiled together provide the evidence that miR-122a 
functions as a tumor suppressor in the liver. Furthermore, by experimenting on a mouse model 
that developed a tumor without inflammation, it has been shown that miR-122a functions as an 
anti-tumor molecule that acts independently of its other functions of liver disease prevention and 
inflammation. Therefore, besides miR-122a being a specific and sensitve diagnostic biomarker, it 
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also has the potential of being used as a therapeutic tool for the treatment of HCC (Bandiera et 
al., 2015).    
 
Fig. 15. MiR-122 is a crucial regulator of liver development and disease. An illustration showing the various 
roles of miR-122 in hepatogenesis and metabolism (red boxes) and its involvement in viral hepatitis and liver 
disease. Also shown is the effect of miR-122 on the activation (+) or inhibition (-) of specific processes. Viral 
origins miR-122 targets are shown in grey boxes, while the host miR-122 targets are illustrated outside boxes. 
Adapted with permission from Bandiera et al., 2015.    
vi. MiR-125a: 
MiR-125a is located on chromosome 19q13, that has been shown to be frequently deleted in 
several types of human cancers. In a study by Scott et al. (2007) it was shown that over-
expression of miR-125a decreased the anchorage-dependent growth, invasion, and migration of 
breast cancer cells through the down-regulation of ERBB2 and ERBB3 in the ERBB2-dependent 
SKBR3 cell line.  Additionally, studies showed that during treatment with trastuzumab, miR-
125a plays a role in inhibiting the proliferation of human gastric cancer cells (Bi et al., 2012). 
MiR-125a was also shown to be down-regulated in non-small cell lung cancer, in which it had 
reverse impact on the invasion and migration of the lung tumor cells. On the other hand, in the 
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case of ovarian cancer, miR-125a over-expression promotes the conversion of very invasive 
tumor cells from a mesenchymal origin to an epithelial morphology, indicating that miR-125a 
negatively regulates EMT (Figure 16) (Jiang et al., 2010).  
In HCC, miR-125a was shown to be frequently down-regulated when compared to normal 
adjacent liver tissue, and it is associated with the tumor progression in HCC patients (Bi et al., 
2012). In HCC cell line, miR-125a ectopic expression could also repress proliferation and 
metastasis in vivo and in vitro. MiR-125a can arrest the translation of the mRNA of the tumor 
suppressor gene, p53, which hinders the expression of HBV surface antigen. Using the miRanda 
and Pic Tar algorithms for analyses showed number of cancer-associated genes, such as ERBB2, 
EDN1, MMP11, ERBB3, MMP14, VEGF-A, and BCL-2L as potential miR-125a target genes. 
In fact, the over-expression of miR-125a did not suppress the ERBB2 or ERBB3 expression, 
which are key players in inhibiting breast cancer proliferation and metastasis. In a study by Bi et 
al., it was found that the expression of MMP11 and VEGF-A is inversely correlated with miR-
125a in HCC tissues. According to these findings, Bi et al. speculated that miR-125a could play 
a role in the inhibition of HCC proliferation and metastasis through the partial down-regulation 
of MMP11 and VEGF-A (Bi et al., 2012).   
Zheng et al. (2015) reported noticeable increase in the expression of miR-125a-5p in 
different fibrotic stages, between F1 and F6, which demonstrated that up-regulation in serum 
miR-125a-5p is associated with the progression of liver disease. Using multivariate logistic 
regression analysis, liver miR-125a-5p was identified as an independent indicator of the 
progression of liver disease. Additionally, Zheng et al. (2015) showed that the serum levels of 
miR-125a-5p were significantly down-regulated in the HCC patient group when compared to 
fibrotic patients and healthy controls. Moreover, serum miR-125a-5p was up-regulated in 
patients with HBsAg (hepatitis B surface antigen) (+) HCC, which highlights the correlation 
between the expression levels of serum miR-125a-5p and hepatitis virus infection. Zheng et al. 
(2015) also reported the correlation between the low expression levels of serum miR-125a-5p 
and poor patient prognosis, which indicates that serum miR-125a-5p could be a good prognostic 
marker for HCC. They also found that changes in serum miR-125a-5p expression levels were 
similar to the expression patterns in liver tissue, suggesting that miR-125a-5p in the serum could 
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be released from liver tissue since the serum miR-125a-5p expression was higher in liver fibrotic 
patients and lower in HCC patients.       
 
Figure 16. MiR-125 Targets. A schematic representation of the involvement of miR-125 in the pathogenesis of 
different diseases. MiR-125 can function either as a cancer repressor or promoter. Adapted from Sun, Lin, & 
Chen, 2013, open access article, no permission.    
vii. MiR 139: 
MiR-139 is located on chromosome 11q13.4 within the second intron of the 
phosphodiesterase 2A (PDE2A) gene. MiR-139-5p is the mature miRNA resulting from a miR-
130 precursor (Qiu et al., 2015). Decreased miR-139 expression has been shown before in 
several digestive malignant tumors, such as gastric, colorectal, parathyroid cancers and 
adrenocortical and squamous cell carcinomas (Li et al., 2014). Wong et al. was the first to report 
that down-regulation of miR-139 in HCC may play a role in suppressing metastasis and cancer 
cells progression through the down-regulation of Rho-kinase 2, a promoting gene for invasion 
and metastasis. Additionally, they demonstrated that the down-regulation of miR-139 was 
significantly correlated with the invasiveness of HCC, in which miR-139 re-expression in HCC 
impacted cell migration and invasion in vitro and in vivo (Wong et al., 2011). On the other hand, 
miR-139 had no effect on HCC cellular proliferation in vitro, and it only slightly reduced tumor 
growth in orthotopic tumors. All evidence demonstrated that the function of miR-139 is 
primarily an anti-metastatic miRNA in HCC (Wong et al., 2011). In 2014, Li et al. used miRNA 
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microarray analysis to show that the expression of miR-139 was significantly lower in 
hepatocellular carcinoma tissues when compared to adjacent peritumoral non-malignant tissues. 
Additionally, expression analysis revealed that the average miR-139 expression in the HCC 
group was 0.009, that was significantly lower than that of the chronic HBV group of 3.516.  
In another study by Gu et al. (2014), they studied miR-139 as a potential HCC miRNA anti-
oncogene. Their results revealed that expression levels of miR-139 were significantly lower in 
HCC tissues compared to normal liver tissue, indicating that miR-139 may play a role in 
hepatocarcinogenesis. They also showed that over-expression of miR-139 suppressed cellular 
proliferation and invasion in HCC. Additionally, apoptosis was significantly induced after miR-
139 transfection. Therefore, they inferred that miR-139 may work as an anti-cancer gene and has 
an important function in inhibiting cell growth and invasion in HCC. They then used miRanda 
algorithm, which identified TCF-4 as a potential tumor suppressor target of miR-139. After 
running a 3’UTR luciferase assay, it was detected that the luciferase activity has increased after 
the miR-139 inhibitor and a 3’UTR vector with the TCF-4 miR-139 target sequence was co-
transfected. The expression of the TCF-4 protein has significantly increased in Hep3B and 
HepG2 cells that experienced miR-139 inhibitor transfection, therefore signifying that miR-139 
uses TCF-4 as a direct target (Gu, Li, & Wang, 2014). Another study by Qiu et al. (2015) 
showed that the increased expression of miR-139-5p suppressed invasion and migration of 
Hep3B and SMMC7721 cells, in addition to controlling EMT-related gene expression. 
Additionally, they found two potential miR-139-5p targets, ZEB1 (zinc finger E-box binding 
homeobox 1) and ZEB2, in which their interaction with miR-139-5p was confirmed through 
conducting luciferase reporter assays. They concluded that the over-expression of ZEB1 and 
ZEB2 in SMMc7721 and Hep3B cells resulted in reversing the miR-139-5p inhibitory effects.       
viii. MiR-145: 
MiR-145 is 22-nt long that a genomic site located in a fragile region of chromosome 5q, 
which shows a frequent loss of heterozygosity (LOH) associated with hepatocarcinogenesis. The 
down-regulation of miR-145 has been shown in different types of cancer such as, lung 
adenocarcinoma, hepatocellular carcinoma, ovarian, colon, and bladder cancers (Wang et al., 
2014). Several transcription factors have been identified that control miR-145 expression, in 
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which it was shown that the silencing of miR-145 is modulated by an epigenetic mechanism. 
Post transcription, before its maturation the pri-miR-145 passes through processing steps that 
involve several factors essential at the post-transcriptional level (Cui, Wang, & Chen, 2014). 
Several studies have shown number of miRNAs regulated by p53, such as miR-107, miR-34a, 
miR-192/215, and miR-145. Sachdeva et al. (2009) reported that p53 could upregulated miR-145 
through the direct binding to the p53 response elements-2 (p53RE-2) in the miR-145 promoter 
(Figure 17). Low levels of miR-145 were shown in laser capture microdissected prostate tissues 
and 47 cancer cell lines to be associated with p53 mutations (Suh et al., 2011). Shi et al. (2012) 
demonstrated that in cervical cancer when glucocorticoid-induced human papillomavirus 
oncoprotein E6 (HPV-E6) is activated, it resulted in the suppression of p53 and miR-145 
expression.  
It was demonstrated that miR-145 inhibits the proliferation of cancer cells and might function 
as a tumor suppressor. It was previously shown in miRNA profiling of HCV-induced HCC that 
miR-145 was down-regulated progressively from cirrhosis through dysplastic nodules to HCC, 
that progresses further to metastasis. Also, the down-regulation of miR-145 in hepatocellular 
carcinoma was shown to be correlated with poor prognosis and histological grade (Wang et al., 
2014). Therefore, it is postulated that miR-145 plays a role in HCC development with a 
malignant potential. It has been reported that in HCC cells, miR-145 was associated with several 
mediators of insulin-like growth factor (IGF) signaling, which is an oncogenic pathway that is 
usually over-activated in HCC (Wang et al., 2014). Wang et al. demonstrated that the down-
regulation of miR-145 happened frequently in human HCC from different etiologies. Restoring 
the expression of miR-145 resulted in inducing cell cycle arrest and inhibiting cell proliferation 
in HCC cells, suggesting that miR-145 functions as a tumor suppressor. 
The down-regulation of miR-145 was shown to be significantly correlated with the TNM 
stage, tumor size and grade, intrahepatic metastasis, and vascular invasion. miR-145 also impairs 
the invasion of HCC cell lines and could potentially target a disintegrin and metalloprotease 17 
(ADAM17), which suggests miR-145 might be used as a target and novel anti-cancer therapy 
tool (Yang et al., 2014). According to Yang et al. the over-expression miR-145 significantly 
down-regulates ADAM17 expression, while the suppression of miR-145 increases ADAM17 
expression. ADAM17 over-expression has been shown in prostate cancer cell lines, gastric 
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tumors, leukemia cell lines, and mammary cancer. ADAM17 is also responsible for inducing 
growth and invasion of HCC and glioma cells (Yang et al., 2014). ADAM17 functions by 
releasing important cell surface molecules, such as tumor necrosis factor-α, EGFR, and adhesion 
molecules, which all play crucial roles in carcinogenesis and metastasis. Yang et al. showed that 
invasion of SMMC-7721 was significantly increased through the inhibition of miR-145 using an 
anti-miR145, suggesting the inhibitory function miR-145 plays in HCC cell invasion. On the 
other hand, the knockdown of ADAM17 using siRNA could cause partial inhibition of invasion 
in SMMC-7721 cells through the induction by anti-miR-145. This finding suggested that 
maintain positive control levels of ADAM17 is a critical component of the tumor-suppressor 
functionality of miR-145 in HCC (Yang et al., 2014).     
 
Figure 17: The down-stream targets of miR-145 and its upstream regulation. Transcription of pri-miR-145 
is promoted by p53 and FoxO1/3, while its transcription is inhibited by RREB1 and C/EBP-β. MiR-145 
processing is regulated at the post-transcriptional level by p53, BRCA1, BCDIN3D and DDX6. IRS-1, EGFR, 
c-Myc, MUC1, FSCN1, OCT4 and SOX2 are the downstream target genes of miR-145. MiR-145 controls 
various cellular processes, such as apoptosis, differentiation, proliferation, angiogenesis, and invasion, through 
the modulation of several oncogenes. Adapted from Cui, Wang, & Chen, 2014, open access article, no 
permission. 
54 
 
IV. AIM OF THE STUDY  
HCC is the third cancer-related cause of death globally, due to several risk factors, of which 
HCV is a major one. The increasing incidence of mortality among HCC patients is attributed to 
delayed diagnosis, recurrence, and metastasis. The current diagnostic tools used to detect HCC, 
such as imaging techniques and serological tumor markers, are not accurate enough to detect 
HCC at early stages. Therefore, accurate, non-invasive, sensitive, and specific diagnostic tools 
are needed to detect HCC at early stages of carcinogenesis. Therefore, the aims of this study 
were to: 
1. Investigate the expression profiles of 8 specific miRNAs: miR-16, miR-34a, miR-122a, 
miR-125a, miR-139, miR-145, miR-199a, and miR-221 in the sera of Egyptian patients 
with HCV-induced HCC.  
2. Evaluate the potential of using these miRNAs as promising non-invasive biomarkers to 
differentiate between normal, fibrotic, cirrhotic, and HCC patients. 
3.  Pick the miRNAs with the highest sensitivity and specificity as potential biomarkers to 
diagnose HCV-induced HCC at early stages of the disease.  
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V. MATERIALS AND METHODS 
A. Sample Collection 
Hundreds of patients are regularly admitted at the Hepato-Gastroenterology Department, 
Theodor Bilharz Research Institute (TBRI), Giza, Egypt, for evaluation of their HCV-related 
chronic liver disease, out of which 165 patients were selected to be enrolled in this study based 
on specific screening criteria. All participants signed informed consents before participating in 
the study, according to the guidelines of TBRI Institute's Human Research Ethics Committee and 
in compliance with the guidelines of the 1975 Declaration of Helsinki as reflected by approval of 
the TBRI and AUC’s human research ethics committee.  
After acquiring the patients’ full medical history, they were subjected to thorough clinical 
examination and assessed by: (a) laboratory testing; including urine and stool analysis, liver 
function tests, serological diagnosis of schistosomiasis and viral hepatitis PCR (which were 
performed routinely for the patients upon admission), (b) ultrasonography, and (c) liver biopsy 
using ultrasound-guided Menghini needle. All procedures, including liver biopsy, were 
medically indicated for patient management. 
Patients were enrolled in the study if they had:  
■ Clinical and laboratory evidences of chronic hepatitis C virus 
■ Circulating anti-HCV (genotype-4) antibodies detected by ELISA 
■ HCV-RNA viraemia detected by nested RT-PCR 
■ Histopathological features of chronic hepatitis C in liver biopsy specimens 
■ Focal hepatic lesion indicative of malignancy detected by abdominal ultrasonography and 
was confirmed to be HCC by histologic assessment  
Patients were disqualified from participating in this study if they had: 
■  Parasitological, serological, histopathological, or ultra-sonographic findings suggestive of 
other etiologies of chronic liver disease, such as:  
– Schistosoma infection 
– Hepatitis B virus infection or dual B and C viral infection 
– Biliary disorders 
– Other malignancies 
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■ HCV-infected patients receiving immunomodulatory interferon-α therapy were excluded as 
well from the study.  
Based on previously published work, patients were divided into three groups. 1) chronic 
hepatitis C (CHC) virus infection group (n= 42), 2) liver cirrhosis (LC) group (n= 45), and 3) 
patients with histopathological findings consistent with HCC (n= 38). Age- and sex-matched 
individuals (n=40) who had undergone laparoscopic cholecystectomy were included in this study 
as controls. After receiving their written consent, wedge liver biopsies were obtained from these 
cases as well as from the control subjects to serve as the control specimens for the 
histopathological studies. All procedures were medically indicated for patient management.  
B. Histopathologic Study 
Assessment of grade of inflammation and stage of fibrosis was carried out in 5 µm thick 
serial sections of formalin-fixed, paraffin-embedded blocks, stained with hematoxylin/eosin and 
Masson trichrome stains. The stage of hepatic fibrosis was determined according to the Metavir 
scoring system (F0, F1, F2, F3 & F4) (Lawrie et al., 2008). The Metavir scoring system is used 
to evaluate the extent of liver inflammation and fibrosis through the histopathological 
examination of liver tissue of HCV patients. The stage indicates the extent of the fibrosis of the 
scarring. The fibrosis stages are as follows: 
 F0: no fibrosis 
 F1: portal fibrosis with no septa 
 F2: portal fibrosis with few septa 
 F3: several septa with no cirrhosis 
 F4: cirrhosis  
  We collected the F0, F1, F2 & F3 in one group, the chronic hepatitis C (CHC) without 
cirrhosis and the F4 only in another group, the CHC with cirrhosis (LC) group. 
C. Urine Analysis 
Mid-afternoon urine samples were collected and centrifuged for 5 minutes at 670x g. After 
centrifugation, drops of the sediment were added onto microscopic slides and examined by light 
microscopy (El-Shafei, 1962). 
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D. Stool Analysis 
Stool analysis was done at TBRI using the merthiolate-iodine-formaldehyde (MIF) method 
for detection of helminthes eggs and protozoal cysts in patients' stool samples (Blagg et al., 
1955). Briefly, 4 ml of stock solution A (merthiolate 0.1%, formaldehyde-glycerin solution 36-
40%) were mixed with 1 ml of stock solution B (iodine 5%, iodied solution 10%) and added to a 
half gram of stool. Mixed samples were filtered through stainless steel sieves and 7 ml of cold 
ether were added. After thorough mixing, test tubes were allowed to stand for 2 minutes and 
centrifuged for 5 minutes at 4200X g. Following centrifugation, drops of the sediments were 
added onto microscopic slides and examined by light microscopy.     
E. Collection of Sera 
Blood samples were collected under complete aseptic conditions by clean venipuncture using 
sterile disposable syringes. About 5 ml of blood were withdrawn from each patient as well as 
controls. Blood was delivered into clean dry test tubes and allowed to clot at room temperature.  
5 ml of whole blood was centrifuged at 1600 rpm for 5 min and the serum was aliquoted into 1.7 
ml eppendorf tubes. Serum samples were stored in tightly closed vials at -80℃ until used.  
F. Liver Function Tests 
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and albumin were 
measured using the Synchron CX5 (Beckman Coulter, Inc., Fullerton, California, USA). The 
levels of alpha-fetoprotein (AFP) were measured using the platinum ELISA kit (R&D Systems, 
Minneapolis, USA). Additionally, the prothrombin time (PT) concentration and des-γ-
carboxyprothrombin (DCP) were assessed in the serum samples using commercially available 
reagents and standard kits.  
G. Detection of Circulating Anti-Schistosoma Antibodies  
An indirect ELISA based on the method of Voller et al. (1976) was applied. Wells of 
microtiter plate (Immulon II, Dynatech Laboratories, USA) were coated with 100 μl/well of 10 
µg/ml of S. mansoni SEA in 0.06 M carbonate buffer, pH 9.6. After overnight incubation at 
room temperature, the plate was thoroughly washed with 0.01 M phosphate buffer saline (PBS). 
Free sites were blocked with 200 ml/well of 1% bovine serum albumin (Sigma Chemicals, St. 
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Louis, USA), in carbonate buffer and incubated for one hour at 37°C. Following incubation, the 
plate was thoroughly washed with PBS. Sera were diluted 1:256 in 0.01 M PBS, and 100 µl were 
delivered/well and the plate was incubated for 30 minutes at 37°C. After incubation, the plate 
was washed as before and 100 µl of 1:1000 dilution of polyclonal goat anti-human horseradish 
peroxidase-labeled IgG antibody (Sigma Chemicals, St. Louis, USA) were added/well. The plate 
was incubated for 30 minutes at 37°C and then washed with PBS. Ortho-phenylenediamine-H2O2 
substrate solution (100 µl/well) was added and the plate was covered and incubated in the dark 
for 20 minutes at room temperature. The reaction was stopped by the addition of 50 µl/well of 8 
N H2SO4. The absorbance of each well was read at 492 nm wavelength using the ELISA 
microplate reader. The cut-off value to differentiate sero-positive from sero-negative samples 
was based on the mean value of healthy subjects + 3 SD and was found to be 0.23. 
H. Detection of Hepatitis B Surface Antigen (HBsAg)    
It was necessary to detect hepatitis B surface antigen in order to rule out contamination with 
HBV that may affect the miRNA expression profile. Hepatitis B surface antigen was detected in 
patients' sera using the HBsAg solid phase sandwich ELISA kit (Axiom Diagnostics, Burstadt, 
Germany). In this assay, wells of a microtiter plate coated with antibody specific to HBsAg were 
incubated with unknown serum samples and a mixture of anti-HBs Ag horseradish peroxidase-
conjugated mouse monoclonal antibodies. After thorough washing to remove excess unbound 
material, a substrate solution containing 3, 3', 5, 5' tetramethylbenzidine and H2O2 was added to 
the wells. Wells containing HBsAg in serum samples developed purple color which changed to 
orange when the enzyme/substrate reaction was terminated with 8 N H2SO4. The amount of color 
in the wells was determined photometrically at 450/620 nm wavelength using the ELISA 
microplate reader and was directly proportional to the amount of bound conjugate and hence the 
concentration of HBsAg in serum samples.  
I. Detection of Anti-HCV (genotype 4) Antibodies 
For the purpose of this study, the focus is on HCV genotype 4 since it is the predominant 
genotype in Egypt. Antibodies to HCV were detected using Version V anti-HCV solid phase 
indirect ELISA kit (Axiom Diagnostics, Burstadt, Germany). In the anti-HCV antibody test, 
serum samples were incubated in micro-wells coated with highly purified antigens containing 
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sequences from the putative core, NS3, NS4 and NS5 regions of HCV. Following thorough 
washing, the captured anti-HCV antibodies were incubated with goat anti-human peroxidase-
labeled IgG antibody. After washing to remove excess unbound conjugate, the bound enzyme 
was visualized by the addition of a substrate solution containing 3, 3', 5, 5'-tetramethylbenzidine 
and H2O2. A purple color developed in the wells containing anti-HCV positive samples. The 
enzyme/substrate reaction was terminated with 8 N H2SO4 to give orange color. The absorbance 
of each well was read photometrically at 450 nm wavelength using the ELISA microplate reader. 
The amount of bound conjugate and hence the color in the wells was directly proportional to the 
concentration of anti-HCV antibody in serum samples.  
J. Detection of HCV (genotype 4)-RNA  
Viral RNA was extracted using the QIAamp Viral RNA kit (Qiagen, Valencia, CA) and 
stored at −80 °C. The serum HCV-RNA level was measured using the One-Step Real Time RT-
PCR according to manufacturer’s protocol (Carlsbad, CA, USA). 
K. RNA Extraction 
The miRNeasy extraction kit (Qiagen, Valencia, CA) was used for the extraction of total 
RNA including miRNAs. For RNA isolation from serum, 200 µl of serum was mixed with 1000 
µl of QIAzol lysis reagent according to the manufacturer’s protocol. Then 200 µl of chloroform 
was added to the sample and the mixed solution was centrifuged for 15 minutes at 12,000 x g at 
4℃. Following the centrifugation, the upper aqueous phase was transferred to a new Eppendorf 
tube. Then, upper aqueous phase was pipetted in the RNeasy MinElute spin column and 
centrifuged at 8000x g for 15 seconds at room temperature. After that, the column was washed 
twice with RWT and RPE buffers; respectively. The RNeasy MinElute spin column was washed 
later with 80% ethanol and centrifuged for 2 minutes at 8000x g. The column was centrifuged for 
5 minutes at full speed in order for the membrane to dry. Finally, for the RNA precipitation, 15 
µl of RNase-free water were added to the column and centrifuged at full speed for 1 minute, and 
the same step was repeated in order to obtain a final elution volume of 30 µl. DNase treatment 
(Qiagen, Valencia, CA) was carried out to remove any contaminating DNA. The RNA 
concentration and quality was determined using the NanoDrop2000 (Thermo Scientific, USA). 
In general, the concentration obtained was ~300 ng/µl of RNA. 
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L. MicroRNA Selection Criteria  
Eight miRNAs were selected for this study: miR-16, miR-34a, miR-122a, miR-125a, miR-
139, miR-145, miR-199a, and miR-221. PubMed search engine was used in order to search for 
the expression profiles of different miRNAs in HCC. The miRNAs were selected based on the 
literature previously published that investigated the expression profiles of serum miRNAs in 
HCC patients as a result of an HCV infection.   
M. Evaluating Serum MicroRNA Expression 
RT (reverse transcription) and qPCR (quantitative PCR) kits made specifically for accurate 
miRNA analysis (Applied Biosystems, Foster City, CA, USA) were used to evaluate expression 
of the 8 chosen miRNAs from serum samples. RT reactions were performed using a TaqMan® 
microRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA).  Each 15 µL 
RT reaction included 7 µL of the RT master mix, 3 µL of the specific miRNA RT primer, and 5 
µL of the total extracted RNA with a concentration ranging between 1 to 10 ng. All RT reactions 
were incubated for 30 min at 16°C, 30 min at 42°C, 5 min at 85°C, and then maintained at 4°C.  
For qPCR, 1.33 µL of the RT product were mixed with 10 µl of TaqMan 2X Universal PCR 
master mixture (No AmpErase UNG), 1 µl of the specific TaqMan MicroRNA assay (Table 1), 
and 7.67 µl of nuclease-free water to bring the final reaction volume of 20 µl according to 
manufacturer protocol. All reactions were run on the StepOnePlusTM Real-Time PCR System 
(Applied Biosystems, Foster City, CA, USA) using the following conditions: 95°C for 10 min, 
followed by 40 cycles at 95°C for 15 sec, and 60°C for 1 min. qPCR was done in duplicates, 
including no-template controls. Relative expression of miRNA was calculated using the 
comparative cycle threshold (Ct) (2−ΔΔCT) method (Schmittgen & Livak, 2008), with miR-39 as 
the endogenous control to normalize the data. The Ct is known as the number of cycles needed 
for the fluorescent signal to cross the threshold in qPCR. ΔCt was calculated by subtracting the 
Ct values of miR-39 from the Ct values of the investigated miRNA. On the other hand, ΔΔCt 
was then calculated by subtracting mean ΔCt of the control samples from ΔCt of the tested 
samples. Fold change of the miRNA was calculated by the equation 2−ΔΔCT while using healthy 
controls as a reference. 
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Table 1. The Assay identifications (IDs) representing the primers and probes for the 8 
microRNAs 
MicroRNA Assay ID Target Sequence 
miR-16 000391 UAGCAGCACGUAAAUAUUGGCG 
miR-34a 000426 UGGCAGUGUCUUAGCUGGUUGU 
miR-122a 000445 UGGAGUGUGACAAUGGUGUUUGU 
miR-125a 002198 UCCCUGAGACCCUUUAACCUGUGA 
miR-139 005364 UCUACAGUGCACGUGUCUCCAGU 
miR-145 002278 GUCCAGUUUUCCCAGGAAUCCCU 
miR-199a 000498 CCCAGUGUUCAGACUACCUGUUC 
miR-221 000524 AGCUACAUUGUCUGCUGGGUUUC 
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VI. STATISTICAL ANALYSIS 
Data were analyzed using Statistical Package for the Social Science (SPSS) version 24 (IBM 
SPSS, Chicago, IL, USA). Continuous variables are expressed as the mean ± standard deviation. 
The analysis of variance (ANOVA) test and the Mann-Whitney (U-test) were used for 
comparisons of continuous (non-discrete) variables. In the current study, Mann-Whitney was 
used because the data is considered nonparametric, since the data does not have a normal 
distribution. ANOVA was used to evaluate expression differences of the chosen miRNAs 
between patients and controls, while the Mann-Whitney was used for the analysis and 
comparison of the patient demographic and biochemical data.  
Finally, Pearson correlation was used to determine the correlation between the miRNA 
expression pattern and the patient group. A significant level of p < 0.05 was used in this test. To 
evaluate the diagnostic accuracy of the 8 miRNAs, a receiver operating characteristic (ROC) 
curve analysis was carried out. The area under the ROC curve (AUC) as well as the 95% 
confidence interval (CI) were calculated for each miRNA in order to determine the specificities 
and sensitivities. For the probability (p) value: p < 0.05 was considered significant, while p < 
0.001 was considered highly significant.      
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VII. RESULTS 
A. Demographic, laboratory investigations, and clinical features of the patients 
Clinically and biochemically healthy, roughly age and gender matched individuals (n=40) 
served as a control population for patients with HCV related liver fibrosis, cirrhosis, and primary 
HCC. Table 2 summarizes the demographic data of both the control subjects and patients, i.e. 
number, age, and gender. The biochemical parameters, i.e. AST, ALT, albumin, alkaline 
phosphatase, PT concentration, AFP, and DCP, are as expected, within the reference range for 
control subjects but significantly elevated in the three patient groups (CHC, LC, and HCC).  
Both the demographic and biochemical profiles of the 42 patients with chronic hepatitis 
C (CHC), 45 patients with liver cirrhosis (LC), 48 patients with HCC, and 40 healthy controls 
enrolled in this study are illustrated in detail in Table 2. Normal controls were age and sex 
matched to the patient group. Serum HCV-RNA revealed that all patients were genotype 4a. All 
enrolled patients had increased ALT, AST, albumin, alkaline phosphatase, PT concentration, 
AFP, and DCP (p<0.001) compared to the control group, in which the AFP and DCP serum 
levels were significantly increased in the HCC patients compared to the CHC and LC patient 
groups (p<0.001). 
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Table 2. Demographic and laboratory data of all patients and controls 
Variables Controls 
(n=40) 
CHC (n=42) LC (n=45) HCC (n=38) 
Age  47.0±3.5 46.4±7.3 51.3±4.7 48.1±4.1 
Gender (M:F) 3:1 3:2 7:5 6:4 
Liver Function Tests (mean±SD) 
AST (U/L) 21.32±1.07 46.14±4.77 a 50.84±5.00 a 76.40±7.34 b 
ALT (U/L) 23.16±1.95 44.12±5.50 a 50.84±5.00 a 76.40±7.34 b 
Alkaline phosphatase (U/L) 189±41 331± 36 a 336±48 a 420±33 b 
Albumin (g/dL) 4.4±0.5 3.60±0.74 3.8±0.72 3.08±0.48 
Prothrombin Concentration  95.6±3.4 89.6±4.8 41.5±11.1 b 69.4±3.7 a 
Alpha-fetoprotein (IU/mL) 3.12±0.08 8.86±0.11 a 10.11±0.11 a 55.18±0.44 b 
DCP (mAU/ ml) 30.42±0.70 121.49±0.59 a 123.62±0.38 a 456.52±0.66 b 
Data are expressed as mean± standard deviations (SD). 
Chronic hepatitis C (CHC); liver cirrhosis (LC); hepatocellular carcinoma (HCC). 
Normal range for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) is up to 
40 IU/L. 
Normal range for alkaline phosphatase is up to 250 U/L. 
Normal range for albumin is 3.5-5 g/dl. 
Normal range for prothrombin concentration is 80-100%. 
Normal range for alpha-fetoprotein is 0.1-9.6 IU/mL. 
mAU/ml =milli-absorbance unit/ml. 
Normal range for des-γ-carboxyprothrombin (DCP) ≤40 mAU/ml.  
ap<0.001 significant increase than control group. 
bp<0.001 significant increase than CHC and LC groups. 
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B. MicroRNAs expression profiles by qPCR 
All miRNAs showed significant increase than control in both the CHC and LC groups 
(p<0.01). Serum levels of miRNA-122a, miRNA-125a, miRNA-139, miRNA-145 and miRNA-
199a were significantly lower (p<0.01) in HCC than in both CHC and LC groups. MiR-34a 
showed significant decrease (p<0.01) in LC compared to the CHC and HCC groups. On the other 
hand, miR-16 was significantly decreased (p<0.01) in the HCC group compared to the CHC 
group. MiR-139 was also significantly decreased (p<0.01) in the LC group compared to the CHC 
group (Table 3; Figures 18 & 19).  
Table 3. The qPCR expression levels of the 8 serum microRNAs in the studied groups 
miRNAs Normal CHC LC HCC 
miRNA-16 14.26±0.69 24.09±0.44** 23.29±0.46** 22.35±0.54** a 
miRNA-34a 27.32±0.19 32.69±0.34** 30.01±0.54** b 32.50±0.94** 
miRNA-122a 19.69±0.33 545.83±0.79** 520.94±0.77** 16.13±0.38c d 
miRNA-125a 20.57±0.54 96.01±4.36** 100.54±0.81** 29.96±0.57** d 
miRNA-139 29.96±0.57 94.63±0.38** 86.02±0.40** e 30.03±0.43d 
miRNA-145 20.65±0.52 85.31±0.53** 80.74±0.59** 20.64±0.57d 
miRNA-199a 80.23±0.72 330.38±0.74** 311.98±0.72** 66.16±0.44c d 
miRNA-221 22.82±0.38 27.17±1.44** 28.22±0.41** 28.51±0.46** 
 **p<0.01 significant increase than control; ap<0.01 significant decrease than CHC; bp<0.01 
significant decrease than CHC and HCC; cp<0.01 significant decrease than control; dp<0.01 
significant decrease than CHC and LC; ep<0.01 significant decrease than CHC 
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Figure 18. Box Plots- Part 1. Box plot diagrams of the expression of miR-16, miR-34a, miR-122a, and miR-
125a, in Hepatitis C virus (HCV)-induced hepatocellular carcinoma (HCC) patients. The box indicates the 25th 
and 75th percentile of the data and the middle line indicates the median. A line extends from the minimum to the 
maximum value, excluding outliers that are displayed as separate points.  
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Figure 19. Box Plots- Part 2. Box plot diagrams showing the expression of miR-139, miR-145, miR-199a, and 
miR-221 in Hepatitis C virus (HCV)-induced hepatocellular carcinoma (HCC) patients. The box indicates the 25th 
and 75th percentile of the data and the middle line indicates the median. A line extends from the minimum to the 
maximum value, excluding outliers that are displayed as separate points.  
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C. Diagnostic performance of circulating MicroRNAs in predicting HCC 
To assess the efficacy of the investigated serum miRNAs for predicting HCC, the AUC 
values (Table 4) were analyzed in order to calculate the sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV) for each microRNAs. The 
sensitivity and specificity of miR-16, miR-34a, miR-122a, miR-125a, miR-139, miR-145, miR-
199a, and miR-221 are (80.95%, 70.59%), (96.77%, 81.82%), (95%, 84.21%), (86.67%, 
83.33%), (85.71%, 64.29%), (90.91%, 77.78%), (87.10%, 72.73%), and (90.32%, 81.82%); 
respectively (Table 5). Table 5 displays the sensitivities and specificities of the 8 miRNAs, 
which were calculated from the ROC curves in order to evaluate the diagnostic potential of the 8 
miRNAs. Out of the 8 miRNAs, miR-122a had the highest sensitivity and specificity, indicating 
that it is a promising biomarker for the early detection of liver cancer. Additionally, miR-125a 
showed the second highest specificity (83.33), therefore indicating its significance in diagnosis, 
but not in screening due to the low sensitivity (86.67).  
Table 4. Area Under the Curve (AUC), Confidence Interval (CI), and p-values for all 8 
circulating miRNAs 
MicroRNAs AUC CI 95% p-value 
miRNA-16 0.716±0.05 0.604 - 0.829 <0.01 
miRNA-34a 0.791±0.04 0.695-0.888 <0.001 
miRNA-122a 0.814±0.04 0.721 - 0.908 <0.001 
miRNA-125a 0.806±0.04 0.729-0.884 <0.001 
miRNA-139 0.863±0.05 0.763-0.962 <0.001 
miRNA-145 0.941±0.02 0.902-0.980 <0.001 
miRNA-199a 0.805±0.03 0.704-0.906 <0.001 
miRNA-221 0.633±0.06 0.510-0.757 <0.05 
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Table 5. The sensitivity and specificity of the 8 microRNAs.  
MicroRNAs Sensitivity Specificity PPV NPV 
miR-16 80.95 70.59 87.18 60.00 
miR-34a 96.77 81.82 93.75 90.0 
miR-122a 95.00 84.21 92.68 88.89 
miR-125a 86.67 83.33 92.86 71.43 
miR-139 85.71 64.29 82.76 69.23 
miR-145 90.91 77.78 93.75 70.00 
miR-199a 87.10 72.73 90.0 66.67 
miR-221 90.32 81.82 93.33 75.0 
PPV: Positive Predictive value       NPV: Negative Predictive Value   
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Figure 20. ROC Curves- Part 1. Receiver operator characteristic (ROC) curve analysis displaying the diagnostic 
power of the miRNAs studied in the hepatocellular carcinoma (HCC) group. Specificities and sensitivities were 
calculated from the ROC curves, in order to determine which of the miRNAs can be used for diagnosis and which is 
important for screening.    
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Figure 21. ROC Curves- Part 2. Receiver operator characteristic (ROC) curve analysis displaying the diagnostic 
power of the miRNAs studied in the hepatocellular carcinoma (HCC) group. Specificities and sensitivities were 
calculated from the ROC curves, in order to determine which of the miRNAs can be used for diagnosis and which is 
important for screening.  
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D. Correlations 
The relationship between certain miRNAs of the 8 investigated, was assessed among the three patient groups (CHC, LC, and 
HCC) using the Pearson correlation. Certain pairs of miRNAs within the same patient group or between two different groups, yielded 
the Pearson correlation coefficient, r, which is a value ranging from +1 to -1 indicating whether the correlation between the two 
certain miRNAs is a positive or negative correlation.    
Table 6. The correlation between miR-16 and miR-34a in the three patient groups 
 HCC16 LC16 CHC16 CHC34a LC34a HCC34a 
HCC16 Pearson 
Correlation 
   r= -0.668**   
Sig. (2-tailed)    .001   
LC16 Pearson 
Correlation 
      
Sig. (2-tailed)       
CHC16 Pearson 
Correlation 
   0.722**   
Sig. (2-tailed)    0.000   
LC34a Pearson 
Correlation 
 0.705**     
Sig. (2-tailed)  0.000     
HCC34a Pearson 
Correlation 
  0.520**    
Sig. (2-tailed)   0.013    
MiR-16 in the HCC group was shown to be negatively correlated with miR-34a in the CHC group. Positive correlation has been 
shown in the CHC group between miR-16 and miR-34a, in the LC group between miR-16 and miR-34a, and in the HCC group for 
miR-34a and CHC group for miR-16.  
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Table 7. The correlation between miR221, miR-122a, and miR-125a in the three patient groups 
 CHC221 LC221 HCC221 CHC122a LC122a HCC122a CHC125a LC125a HCC125a 
CHC221 Pearson 
Correlation 
 0.629**    r=0.508*    
Sig. (2-tailed)  p<0.001    p<0.01    
LC221 Pearson 
Correlation 
       -0.765**  
Sig. (2-tailed)        p<0.000  
CHC122a Pearson 
Correlation 
        0.598** 
Sig. (2-tailed)         p<0.001 
LC122a Pearson 
Correlation 
      -0.452*   
Sig. (2-tailed)       p<0.05   
CHC125a Pearson 
Correlation 
    -0.452*    0.489* 
Sig. (2-tailed)     p<0.05    p<0.05 
Negative correlations were shown between miR-221 and miR-125a in the LC group, and miR-122a in the LC group and miR-125a in 
the CHC group. miR-221in the LC and CHC groups, miR-122a in the HCC group and miR-221 in the CHC group, miR-125a in HCC 
and miR-122a in CHC, and miR-125a in HCC and CHC groups, were all positively correlated.  
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 Table 8. The correlation between miR139, miR-145, and miR-199a in the three patient groups 
 
 
CHC139 LC139 HCC139 CHC145 LC145 HCC145 CHC199a LC199a HCC199a 
CHC139 Pearson 
Correlation 
     r=0.492*    
Sig. (2-tailed)      0.020    
HCC139 Pearson 
Correlation 
       -0.577**  
Sig. (2-tailed)        0.005  
LC145 Pearson 
Correlation 
      r=0.532*   
Sig. (2-tailed)       0.011   
HCC145 Pearson 
Correlation 
0.492*         
Sig. (2-tailed) 0.020         
LC199a Pearson 
Correlation 
         
Sig. (2-tailed)          
*Correlation is significant at the 0.05 level 
**Correlation is significant at the 0.01 level 
 
MiR-199a in the LC group and miR-139 in HCC were the only two groups negatively correlated. On the other hand, the positively 
correlated groups were, miR-145 in HCC and miR-139 in CHC, and miR-199a in CHC and miR-145 in LC.  
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VIII. DISCUSSION  
HCV infection is a serious global health issue. It has been estimated that more than 80 
million individuals suffer from HCV chronic infection worldwide, and that 3-4 million new cases 
are infected annually, in addition to approximately 350,000 HCV-related deaths. Egypt is known 
to be the country with the highest prevalence of HCV infection worldwide, with genotype 4 
being the most common (Mahmoud et al., 2013; Kandeel et al., 2017). In 2008, the Egyptian 
government conducted the Egyptian Demographic Health Survey (EDHS) on a big nationally 
representative sample, which estimated the incidence among the 15-59 years age group of HCV 
antibodies as well as HCV RNA to be 14.7 and 9.8%; respectively. According to the population 
survey and the EDHS conducted in 2008, it was predicted that more than 6.8 million patients 
between the age of 15-59 years had HCV antibodies, out of which more than 4.5 million patients 
showed active HCV infection (Kandeel et al., 2017). HCV infection is mainly asymptomatic 
with only minor symptoms at the acute stage of the disease. HCV infection usually results in 
fibrosis, cirrhosis, eventually leading to the development of HCC (Elgharably et al., 2017).  
HCC represents a major health issue worldwide, which is characterized by varied prognosis 
as well as its biological and clinical heterogeneity, due to different management approaches 
(Cabibbo et al., 2016). HCC is still an extremely poor prognostic cancer that remains one of the 
most common and aggressive human malignancies worldwide. The early diagnosis of HCC is of 
great clinical desirability, since it promises good prognosis if the patient could get early surgical 
treatment. Currently, α-AFP is one of the main biomarkers used clinically for diagnosing primary 
HCC; however, its sensitivity and specificity are not satisfying (Aubé et al., 2017); therefore, 
novel non-invasive biomarkers for early HCC diagnosis are greatly needed. 
Research from recent studies revealed that circulating miRNAs are potential diagnostic 
biomarkers and prognostic factors in various kinds of diseases, especially in the field of cancer. 
Mitchell et al. (2008) demonstrated the presence of circulating tumor-derived miRNAs in blood 
by using a mouse prostate cancer xenograft model system, in which he showed measurements 
obtained from plasma were strongly correlated with those obtained from sera, suggesting that 
both serum and plasma samples would be adequate for measuring specific miRNA expression 
levels. In another study, Chen et al. (2008) demonstrated that by using serum directly or by 
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extracting RNA from the serum, it is possible to identify unique miRNA expression profiles for 
lung cancer, colorectal cancer and diabetic patients compared with healthy subjects. Circulating 
miRNAs have also been postulated as novel biomarkers for ovarian cancer (Resnick et al., 2009; 
Taylor, 2008), pancreatic cancer (Ho et al., 2010), and colorectal cancer (Huang et al., 2010; Ng 
et al., 2009). Although the clinical significance of these findings has not been elucidated in 
detail, those findings demonstrated that circulating miRNAs could be used as non-invasive 
diagnostic or prognostic biomarkers for cancer. 
Several studies have demonstrated the significant association of miR-16 in 
hepatocarcinogenesis, Qu et al. (2011) showed that when combining miR-16 expression with the 
traditional liver biomarkers, the diagnostic accuracy is highly improved. As was shown in the 
results, miR-16 was significantly up-regulated in the HCC patient group. However, according to 
Qu et al. miR-16 is down-regulated in HCC patients, in which HCV infection was the underlying 
etiology in the study subjects. In 2014, Ge et al. also showed that miR-16 is down-regulated in 
the sera of HCC patients, which in combination with let-7f and miR-21 they can be used 
biomarkers for estimating the tumor size as well as recurrence (Ge et al., 2014). As a matter of 
fact, in 2009 Huang et al. revealed through microarray analysis that miR-16 was up-regulated in 
HCC patients with mixed etiologies compared to normal subjects (Huang et al., 2009). 
Also, unlike what has been described in the literature, in the current study, miR-34a was up-
regulated in HCC patients compared to the healthy subjects. Both Miao et al. (2014) and Yu et 
al. (2014) have shown that miR-34a was down-regulated in HCC. The conflicting results 
between the current study and what has been published in the literature might be attributed to a 
number of factors that impact the expression pattern of miRNAs in different studies. Such factors 
include the heterogeneity of the cancer patients, such as the tumor stage, treatment, and etiology. 
The type of specimen is also a major factor since different samples are continuously studied, like 
serum, plasma, paraffin-embedded tissue, or formalin-fixed tissue (Shen et al., 2016). 
Additionally, the differences in sample collection, processing, and preservation are all factors 
that might impact the outcome of the expression analysis. Different RNA isolation techniques, 
the quality and concentration of the isolated RNA, and the detection methods, are all additional 
factors that might impact the miRNA expression profile. Even if the study was meticulously 
designed, using various methods and housekeeping transcripts for miRNA expression 
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normalization might result in experimental bias and therefore yielding different miRNA 
expression profiles. Thus, normalization is essential in eliminating most of the non-biological 
variations in order to ensure accurate miRNA expression profiles (Shen et al., 2016).     
In the current study, miR-221 was up-regulated as well with a sensitivity and specificity of 
90.32 and 81.82; respectively. MiR-221 is known to be up-regulated in HCC and it plays 
important roles in hepatocarcinogenesis, responsible for proliferation, migration and invasion, 
apoptosis, clonogenicity, and G1 arrest, while targeting the following genes: BMF, BBC3, and 
ANGPTL2 (Shen et al., 2010). In 2011, Li et al. demonstrated that miR-221 was highly 
expressed in the sera of HCC patients; however, it was concluded that it was not statistically 
significant and might not serve as a reliable diagnostic biomarker for HCC (Li et al., 2011). On 
the other hand, Turchinovich et al. (2011) showed that the up-regulation of miR-221 in the sera 
of HCC patients was associated with decreased survival rate.  
The expression of miRNA-122a is specific to the liver, in which it is considered 70% of the 
entire miRNA expression in the liver. Current studies have shown that the expression levels of 
miRNA-122a have declined during the process of hepatocarcinogenesis; hence miRNA-122a can 
function as a tumor suppressor. Our findings were consistent with previous studies (Luo et al., 
2013; Ezzat et al., 2014; Motawi et al., 2016), in which we observed decline in the levels of 
miRNA-122a in HCC patients with HCV infection compared to the control individuals. On the 
other hand, the levels of miRNA-122a increased significantly in the CHC and LC groups 
suggesting that during the process of hepatocyte injury miRNA-122a levels increase drastically, 
and then decline significantly after the liver has entered carcinogenesis. On the contrary, 
according to a study by Jiang et al. (2015), the serum levels of miRNA-122a have been shown to 
be elevated in HCC patients compared to healthy individuals. Also, as presented in our results, 
the ROC curve has demonstrated that out of the eight miRNAs investigated, miRNA-122a has 
the highest specificity and sensitivity making it an eligible candidate as a liver tumor marker.  
Coulouarn et al. (2009) showed that the overall survival of patients with high and low 
expression of miR-122a was 83.7 ± 10.3 and 30.3 ± 8.0 months, respectively, while the 
inhibition of miR-122a was also associated with low status of differentiation and large tumor 
size. Halász et al. (2015) revealed a reduced level of miR-122a in stage F4 fibrosis as compared 
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to stage F0, in which miR-122a showed a negative correlation with fibrosis stage in fibrotic liver 
samples and intriguingly, also with liver stiffness (LS) values. These findings are supported by 
reports of a negative correlation between miR-122a and fibrotic stage in chronic HCV infection, 
HCV-based HCC, and cirrhosis (Marquez et al., 2010; Morita et al., 2011), in addition to 
observations of a decreased level of miR-122a in non-alcoholic fatty liver disease (NAFLD) 
(Kerr et al., 2011; Lakner et al., 2011) and in HCC studies (Borel et al., 2012).  
Loss of miR-122a seems to be a frequent event in hepatoblastoma (Gyugos et al., 2014), 
which correlates with migration, invasion and in vivo tumorigenesis, whereas HCC cells 
expressing miR-122a retain an epithelial phenotype (Karakatsanis et al., 2013). MiR-122a is 
considered a differentiation marker for hepatocytes (Cairo et al., 2010) and a lower level of miR-
122a might also reflect a lower degree of differentiation in the embryonal component. In 
addition, reduced expression of miR-122a is essential for the normal function of hepatocytes; 
which positively regulates cholesterol, triglyceride accumulation, and fatty acid metabolism (Hu 
et al., 2012), constituting 70% of the total miRNA pool of the liver. 
The majority of studies that focused on the expression profiles of miRNA in HCC have 
shown that in most cases the progression of the malignancy is correlated with the down-
regulation of the miRNAs. However, it needs to be taken into consideration that at the post-
transcriptional level, miRNAs regulate hundreds of targets that are part of many signal 
transduction pathways, which makes the role of miRNAs in the process of hepatocarcinogenesis 
very complicated. Bi et al. (2012) showed that the expression of miR-125a is lower in HCC 
malignant tissue compared to non-tumor adjacent liver tissue, and that the low expression level 
of miR-125a was associated with the progression of the disease as well as poor prognosis. In 
addition to the lower expression observed in tissues, also low expression of miR-125a was seen 
in HCC cell lines. In fact, it has been shown that the in vitro and in vivo ectopic expression of 
miR-125a can lead to inhibition of proliferation, migration, and invasion of the HCC cells (Bi; et 
al., 2012).  
Unlike what the literature and other studies have shown, the expression level of miR-125a in 
our study was significantly higher in the HCC patient samples compared to the control group, 
which might be due to the fact that HCC was a result of a genotype 4 HCV infection. In addition, 
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the ancestral background and the gene pool of the current study is different than that of the other 
studies that demonstrated the down-regulation of miR-125a. Therefore, factors such as the 
genotype of HCV as well as the ancestral background of the study group might have had an 
impact on the expression profile of miR-125a. On the other hand, very high expression levels of 
miR-125a were observed in the CHC and LC patient groups. However, very low expression of 
miR-125a was reported in the HCC group, 29.96±0.57, compared to that of the CHC and LC 
groups, 96.01±4.36 and 100.54±0.81; respectively. Same as miR-122a, miR-125a showed high 
sensitivity and specificity, 86.67 and 83.33; respectively, suggesting its diagnostic value. 
Therefore, both miR-122a and miR-125a can be used together for the early detection of HCC 
induced HCV due to their high sensitivities and specificities.  
Same as miR-125a, according to previous studies the expression level of miR-139 has been 
shown to be significantly lower in HCC patient samples compared to control individuals. MiR-
139 was shown to play an important role in the hepatocarcinogenesis, in fact high expression 
levels of miR-139 were shown to inhibit cellular proliferation and invasion in malignant liver 
cells. In addition, in miR-139 transfected cells, apoptosis was shown to be highly induced, which 
suggests that miR-139 can act as a tumor suppressor through the inhibition of cell proliferation 
and invasion in HCC (Gu, Li, & Wang, 2014; Wang et al., 2014). As shown in our results, the 
expression levels of miR-139 have increased in the HCC patient group compared to the control 
group, which contradicts what has been reported in other studies, while the CHC and LC patient 
groups showed significant increase of miR-139 expression. As a matter of fact, a possible 
explanation for the elevated expression levels for miR-125a and miR-139 in the HCC patient 
group can be due to the fact that HCV infection is the underlying cause for the HCC patients in 
the study, which might have an effect on the expression level of the two miRNAs. Although 
according to the literature, the HCV infection should not be affecting the expression levels after 
the patient develops HCC; however, no study has examined that with HCV genotype 4. All 
patients in our study have developed HCC as a result of a genotype 4 HCV infection, which may 
have resulted in the high expression level of miR-125a and miR-139 contradicting other studies. 
As a matter of fact, since tumor cells are smaller in number compared to the rest of the cells in 
the body, most of the changes in the expression levels of specific circulating miRNAs result from 
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the body’s response to carcinogenesis, thus making it difficult to generate unique miRNA 
signatures for the detection of specific types of tumors (Qi et al., 2016). 
MiR-145, was another miRNA tested among the miRNAs panel investigated, in which its 
expression level showed no difference between the normal controls and the HCC patient group. 
Same as the rest of the miRNAs investigated, miR-145 in the CHC and LC groups showed 
significant increase compared to the control and HCC groups. Among several studies, Wang et 
al. (2014) demonstrated that miR-145 was significantly down-regulated in HCC patient samples 
as well as HCC cell lines. As a matter of fact, the down-regulation of miR-145 was greatly 
linked to intrahepatic metastasis, tumor size, vascular invasion, and tumor grade, all suggesting 
that miR-145 acts as tumor suppressor and its decreased expression results in the progression of 
the hepatocarcinogenesis (Wang et al., 2014; Yang et al., 2014). Therefore, determining the 
tumor size and grade in the HCC patients enrolled in the current study will be a key factor in 
understanding the such contradicting expression profiles between what has been reported in the 
literature versus the current study.  
The last miRNA we investigated was miR-199a, which was down-regulated in the HCC 
patient group compared to the control group, while it was significantly upregulated in the CHC 
and LC groups. The down regulation of miR-199a has been reported in several studies; in fact, 
miR-199a has been one of the most consistently reported miRNAs to be involved in HCC. MiR-
199a is the third highly expressed miRNA in the liver, and in the case of HCC it has been shown 
to be down-regulated especially in patients with HCV, HBV infections, and alcohol abuse (Diaz 
et al., 2013). The down-regulation of miR-199a in HCC patients has been associated with poor 
prognosis. The identification of miRNAs associated with HCC is crucial to developing new 
diagnostic and therapeutic tools with high specificity and sensitivity in order to combat this 
vicious human cancer.   
Correlation is a technique often used to study the relationship between two quantitative and 
continuous variables. In the current study, we used Pearson correlation to calculate the Pearson’s 
correlation coefficient (R), a value between +1 and -1 that indicates the strength of the 
association between two variables (Chen et al., 2008). The correlation between miR-16 and miR-
34a was investigated among the three patient groups, in which miR-34a and miR-16 in CHC and 
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LC were positively correlated as well as miR-34a in HCC and miR-16 in CHC. On the other 
hand, miR-34a in CHC and miR-16 in HCC showed a highly significant negative correlation. 
More positive correlations were shown among the following groups: miR-221 in LC and CHC, 
miR-122a in HCC and miR-221 in CHC, miR-125a in HCC and miR-122a in CHC, miR-125a in 
HCC and CHC, indicating for example if there is low expression of miR-122a in HCC, then 
miR-221 will be down-regulated as well in CHC. miR-125a in CHC and miR-122a in LC, and 
miR-125a and miR-122a in LC were shown to be negatively correlated, meaning that if one is 
over-expressed the other will automatically show a decreased expression. Finally, miR-145 in 
HCC and miR-139 in CHC as well as miR-199a in CHC and miR-145 in LC were positively 
correlated, while miR-199a in LC and miR-139 in HCC were negatively correlated. Establishing 
the Pearson correlation between different miRNAs among the patient groups has a significant 
diagnostic value because it indicates if two miRNAs were for example positively correlated in 
one or more patient group, then only one of these miRNAs is needed to be investigated. For 
example, in the CHC group, the r value for the correlation between miR-34a and miR-16 was 
shown to have a positive correlation of 0.722, which means that if miR-34a is up-regulated, then 
miR-16 will be up-regulated as well, and vice versa. Therefore, from a diagnostic perspective, if 
for instance miR-34a was found to be elevated, then it can be inferred that miR-16 will be 
elevated as well.  
Finally, circulating miRNAs in liver cancer patients represent promising biomarkers that 
possess great stability and reproducibility in peripheral blood. MiRNAs have the potential to be 
used in several clinical aspects of cancer management, such as cancer screening and early 
diagnosis, evaluating the malignancy in order to choose a surgical or a non-surgical approach, 
and to check for recurrence and cancer dynamics (Kawaguchi et al., 2016). Additionally, 
circulating miRNAs can be versatile, as it is anticipated that they will be used as efficient 
therapeutic agents in human tumors. MiRNAs possess a major advantage as therapeutic agents, 
which is the fact that a single miRNA targets several genes that function in the same pathway 
(Aqeilan et al., 2010). Due to their non-invasive and reproducible nature, it is anticipated that in 
the future circulating miRNAs will be efficient biomarkers and reliable indicators in pretreatment 
options.  
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IX. CONCLUSION  
As was shown in the results, measurement of serum levels of miR-122a, miR-125a, miR-
139, miR-145, and miR-199a can help to differentiate HCC from CHC and LC. The serum 
levels of miRNA-122a, miRNA-125a, miRNA-139, miRNA-145 and miRNA-199a were 
significantly lower (p<0.01) in HCC than in both CHC and LC groups; therefore, this panel of 
miRNAs provide high accuracy for the early detection of HCC. On the other hand, measurement 
of serum levels of miR-16, miR-34a, and miR-221 were shown to have a prognostic rather than 
a diagnostic value since they did not significantly differentiate the HCC group from the CHC 
and LC groups. Moreover, according to their expression patterns among the patient groups, 
miR-16, miR-34a, and miR-221, can be used to detect liver injury, such as fibrosis and cirrhosis, 
due to their significant elevation in comparison to the control subjects. Additionally, highly 
significant correlation was established between different miRNAs within the same patient group 
or between two different groups, indicating a diagnostic potential for the early detection of 
HCC. MiR-122a showed the highest specificity and sensitivity, indicating that serum miR-122a 
is a novel and potential non-invasive biomarker for HCV-induced HCC. Finally, following miR-
122a, miR-125a was shown to be a great potential HCC biomarker as well since it showed the 
second highest specificity, indicating its significance in diagnosis, but not in screening due to 
the low sensitivity.  
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X. FUTURE PERSPECTIVES  
After years of extensive research, there is no doubt that miRNAs play a critical role in 
carcinogenesis and control the development and progression of human cancers. Although 
scientists in the last decade have managed to answer a lot of questions regarding the contribution 
of miRNA to carcinogenesis, there still remains number of unanswered questions before using 
miRNA profiling in the clinical practice. One of the major challenges that will be faced in the 
future is establishing specific cancer miRNA signatures that are extremely reproducible and 
independently predictive of the tumor in order to improve cancer diagnosis and therapy (Leva & 
Croce, 2013). Therefore, major research is being conducted to overcome such challenges in order 
to utilize miRNAs as an accurate diagnostic tool for the early detection of human cancers as well 
as an effective therapeutic tool.    
Using circulating miRNAs as biomarkers in cancer patients presents several challenges. First 
of all, the expression profile of a single miRNA cannot be used as a biomarker of one specific 
tumor, due to the fact that several miRNAs are highly expressed in more than one tumor as well 
as other diseases. Several miRNAs display opposite expression patterns in different types of 
cancers, such as the family of miR-200 (Kawaguchi et al., 2016). Therefore, using the expression 
patterns of several miRNAs rather than one and different miRNA signatures might serve as a 
more reliable biomarker depending on which tumor type is being diagnosed. Large-scale studies 
with well-defined methods are in demand in order to clinically implement the use of circulating 
miRNAs in diagnosing patients with liver cancer (Kawaguchi et al., 2016).    
In order to establish an accurate diagnostic tool using miRNAs, the diagnostic panel should 
include the following (Qi et al., 2016 & Carter et al., 2017): 
1) Unique miRNA signatures with specificity and sensitivity for each type of human cancer 
2) Precise variations triggered by extrinsic and intrinsic factors 
3) Specific procedures for standard normalization along with accurate internal controls 
4) Well-defined reference range of specific circulating miRNAs in healthy individuals 
5) Specified concentration kinetics of individual circulating miRNAs  
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يىة أمىراد الكبىد  وبنىالا علىى تلىك المعلومىات يماىا اسىتخداي هى ا التيييىرات الاينيىة وابحمىاد النوويىة فىى الىدي شم  ىرات حيو 
 للكفف عا ابمراد 
 
  أ د/ منى شامل زهيرى   الباحث الرئيسى:
  
 أ د/ محمىىد عبىىاس ٬د/ هىىدى أطولالىىب ٬صىىى ى نىىاجىأ د/ فىىاتا م٬د/ لبنىىى مىىراد  ٬أ د/ ايمىىان ابهىىوانى ٬: البىىاحثون المفىىارشون 
  د/ مروة حسا ٬ ٬ ميس
 ابحمىاد النوويىة الدقيقىة ومقارنتهىاو نحىا نقىوي طدراسىة  التليىف الكبىدى الوبىائى النىاتف عىا فيىروس سىىأنى  تعىانى مىا مىرد 
حماد النووية الدقيقىة مريض لإماان التوصل الى معرفة عدد معيا ما اب 561وسوف نستعيا بعدد  بماموعة ما ابصحال
السابحة فى الدي حيث يماا استخدامها شم  ر لتفخيص وتىور المرد قبل البدل فى افراز النسيف الضاي فى الكبد وذلك فىى 
 حالات الالتهاب الكبدى الوبائى سى المنتفر فى مصر 
 المىلوب ما المفارك فى ه ا الدراسة:
 ملليليتر  5ة ، سوف نقوي بأخ  التاريخ المرضى وأخ  عينة دي لو وافق  على الا تراك معنا فى ه ا الدراس 
 لمرد قبل تىورا استخداي التيييرات الاينية وابحماد النووية فى الدي شم  رات حيوية للكفف عا ا: ال ائدة
 : لاتوجدالاعراد الاانبية
 اماانية قبول أو رفض المفارشة:
أن  غير مابر اللاقا على المفارشة و ش لك ما حقك الانسىحاب مىا الدراسىة وقتمىا تفىال بعىد اطىلاب الىبيىب المسى ول طىدون  
 أن ي ثر قرارك على الرعاية الىبية التي تحصل عليها  
 ما سيعلم بمفارشتك فى البحث : 
الحرية فى اطلاب مىا تريىد مىا أهلىك و أصىدقائك  ابلبال المس ولون عا البحث و ش لك الممرضات المعاونون لهم و لك مىلق
للمسى وليا  كما أن المعلومات الخاصة بحالتك المرضية وعلاجك ستكون مح وظة بىريقة آمنة غير مسموح بىالإللا  عليهىا  لا
 عا البحث 
 هل لديك أى است سارات أخرى ؟ 
 08878351110تور الباحث الرئيسى تلي ون : فى حالة رغبتك فى لرح أى س ال أثنال الدراسة يمانك توجيهه  لى الدش
  211
 
 
فىى حالىة رغبتىك فىى لىرح أى  ىاوى أثنىال الدراسىة يمانىىك توجيههىا  لىى الاسىتاذ الىدشتور رئىيس لانىة أخلاقيىات البحىث العلمىىى 
   11490080010بمعهد تيودور طلهارس للأبحاث  تلي ون: 
 فارشة فى الدراسة على الم قرأت و فهم  ووافق أقر أنا الموقع أدناا،أننى قد 
 توقيع المفارك :
 عنوان المفارك :
 التاريخ :                           الرقم القومى : 
 تلي ون المفارك :
 التاريخ :  توقيع الفاهد : 
 التاريخ :  : توقيع الباحث
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C. Institutional Review Board (IRB) 
i. The American University in Cairo 
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ii. Theodor Bilharz Research Institute 
 
